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A data analysis pipeline for the discovery of biomarkers on cancer cell lines by
label-free shotgun proteomics has been developed and implemented in this thesis.
Speciﬁcally the solution has been optimized for the analysis of secretomes of cancer
cell lines measured in spectral counts by LC-MS/MS. Along the development it has
been shown the incidence and relevance of batch eﬀects in the comparative analysis
of label-free proteomics by LC-MS/MS. Also the features providing reproducibility
to potential biomarkers have been identiﬁed. The model has been developed on
empirical data obtained from a series of spiked experiments, and with the help of
simulations, to evaluate its performance. The pipeline comprises an exploratory
data analysis (EDA) R/Bioconductor package based on multidimensional analysis
tools, and a R/Bioconductor inference package based on generalized linear models
(GLM) with Poisson or negative binomial distributions, or the quasi-likelihood
GLM extension. Two graphical interfaces have also been developed to ease the
use of the provided solution in a MS lab by non experts. The designed model is
devised to discover diﬀerentially expressed proteins in cancer cell line secretomes,
using the cell as the unit of interest. The model allows blocking factors as a mean
for batch eﬀects correction. The normalization to cell units is embedded in the
model through the use of oﬀsets, and no previous data treatment is required. The
two packages developed are called msmsEDA and msmsTests, and allow for:
• Dataset quality assessment.
• The identiﬁcation of outliers
• The identiﬁcation of confounding factors or batch eﬀects.
• The discovery of potential biomarkers by using the distribution best ﬁtting
the available data.
• Improving the degree of reproducibility by a post test ﬁlter based of eﬀect
size and signal levels.
Diﬀerent papers have been published in proteomics journals both, develop-
ing each data treatment step, and demonstrating its use and value in biological




En la tesi s’ha desenvolupat, dissenyat i implementat una solucio´ per l’ana`lisi de
dades de proteo`mica en descobriment de biomarcadors. Espec´ıﬁcament la solucio´
s’ha optimitzat per l’ana`lisi de secretomes de l´ınies cel.lulars de ca`ncer. Durant
el desenvolupament de la metodologia s’ha demostrat la incide`ncia i relleva`ncia
dels efectes batch en l’ana`lisi comparatiu de pe`ptis sense marcar per LC-MS/MS.
Aix´ı com les caracter´ıstiques que identiﬁquen un potencial biomarcador com a
reproductible. Els models s’han desenvolupat amb l’ajut de dades emp´ıriques
obteses de mostres amb mescles controlades de prote¨ınes, i de simulacions. La
solucio´ informa`tica que implementa el model desenvolupat consta de dos paquets
R/Bioconductor, amb les respectives interf´ıcies gra`ﬁques que faciliten el seu u´s a
no experts. El primer paquet, msmsEDA, consta de funcions u´tils en l’ana`lisi explo-
rato`ria de dades, i permet avaluar la qualitat del conjunt de dades d’un experi-
ment de LC-MS/MS basat en comptatge d’espectres, aix´ı com explorar l’eventual
prese`ncia de valors extrems, factors de confusio´, o d’efectes batch. El segon paquet,
msmsTests, encapsula funcions per la infere`ncia en el descobriment de biomarca-
dors. Els tests ajusten un model GLM que permet la inclusio´ de factors per blocs
com a mecanisme de correccio´ d’efectes batch, i que incorpora una normalitzacio´
generalitzada mitjanc¸ant la te`cnica dels oﬀsets que permet la comparacio´ de se-
cretoma al nivell d’una cel.lula. Les distribucions implementades so´n la de Poisson
i la binomial negativa, aix´ı com l’extensio´ de la quasiversemblanc¸a. En conjut, el
model desenvolupat i la implementacio´ informa`tica que se’n ha fet permet:
• Avaluar la qualitat d’un conjunt de dades de LC-MS/MS basades en SpC.
• Identiﬁcar valors extrems.
• Identiﬁcar la prese`ncia de factors de confusio´ o d’efectes batch.
• El descobriment de biomarcadors emprant la distribucio´ que millor s’ajusti
a les dades.
• Asegurar un bon nivell de reproductibilitat merce`s a un ﬁltre post-test que
te´ en compte la intensitat del senyal i la mida de l’efecte.
Els paquets, llur documentacio´ i tutorials, estan disponibles a bioconductor.org,
i les interf´ıcies gra`ﬁques amb tutorials i manuals d’usuari a github.com.
xi
S’han publicat articles en revistes internacionals de proteo`mica desenvolupant
cada pas en el tractament de dades, i demostrant el seu u´s i aplicabilitat en expe-
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Aquest resum del treball presentat consisteix en una introduccio´, que situa i con-
textualitza el treball desenvolupat, un apartat on es ﬁxen els objectius, una seccio´
de resultats on es presenten els treballs publicats i el software desenvolupat, una
discussio´ on s’expressen mancances i limitacions, i s’assenyalen possibles noves vi-
es de recerca, i una ﬁnal de conclusions on es recullen les aportacions al camp
estudiat.
1.1 Introduccio´
En el que portem de segle s’ha viscut l’emerge`ncia d’un nombre de tecnologies d’alt
rendiment en el camp de les o`miques, que han despertat altes expectatives com
a eines en el descobriment de biomarcadors u´tils en diagno`stic i prono`stic cl´ınics.
Aquestes tecnologies han comportat l’emerge`ncia d’un nou paradigma estad´ıstic, el
de moltes-variables-poques-re`pliques que constitueix un problema de dimensionali-
tat [Bellman, 1961]. La primera d’aquestes tecnologies, els microarrays d’expressio´
(MA), emprats per mesurar d’un sol cop el transcriptoma complet d’una mostra
biolo`gica, s’ha enfrontat me´s que cap altra als reptes de no decebre en les seves
capacitats, i de resoldre els corresponents reptes estad´ıstics i d’ana`lisi de dades.
Si be´ des del principi es va recone`ixer la necessitant d’un bon disseny experi-
mental en els estudis amb microarrays, tambe´ es van anar evidenciant problemes
de reproductibilitat en biomarcadors que havien estat publicats amb altes taxes
de sensibilitat i especiﬁcitat [Kuo et al., 2002; Tan et al., 2003; Ransohoﬀ, 2004;
Marshall, 2004; Dupuy & Simon, 2007; Borst & Wessels, 2010; Baggerly & Coom-
bes, 2009; Potti et al., 2011]. Com a resposta a l’aparent atzucac es va constituir
el MicroArray Quality Control Consortium (MAQC) amb autoritats acade`miques,
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de l’administracio´ (FDA), i de la indu´stria per avaluar els factors que podien in-
tervenir en la reproductibilitat de resultats entre diferents laboratoris i diferents
plataformes [Shi et al., 2006] (ﬁgura 2.1), i per construir i avaluar discriminadors
basats en resultats de microarrays [Shi et al., 2010].
Aquest treball prete´n explorar temes espec´ıﬁcs en proteo`mica comparativa, i
traslladar i implementar algunes de les llic¸ons primer apreses amb microarrays en
la fase de descobriment de biomarcadors.
1.1.1 Biomarcadors
Un biomarcador es pot deﬁnir com una mole`cula o conjunt de mole`cules, quin nivell
e´s indicatiu d’un estat biolo`gic [Madu & Lu, 2010]. En cl´ınica un biomarcador e´s
rellevant com a predictor de l’estat d’una malaltia (diagno`stic) o de l’evolucio´
de la malatia (prono`stic). Els biomarcadors de diagno`stic so´n mesures basals que
proporcionen informacio´ sobre quins pacients es poden beneﬁciar d’un tractament.
Els biomarcadors de prono`stic so´n mesures de pre-tractament informatives sobre
l’evolucio´ de la malaltia i el seu resultat en el llarg termini. En aquest sentit es
poden considerar com a mesures de risc que poden aconsellar tractaments me´s
agressius [Madu & Lu, 2010].
El descobriment de biomarcadors (BD) constitueix nome´s el primer pas en el
seu desenvolupament. Un proce´s complex i llarg que inclou les segu¨ents etapes
[Rifai et al., 2006]:
• Descobriment: Identiﬁcar candidats a biomarcadors.
• Qualiﬁcacio´: Conﬁrmar l’expressio´ diferencial en el ﬂuid biolo`gic d’intere`s
per una te`cnica de me´s baix rendiment i me´s exacta.
• Validacio´: Determinar la sensibilitat i l’especiﬁcitat amb mostres indepen-
dents.
• Desenvolupament en assaig cl´ınic: Establir la sensibilitat i l’especiﬁcitat
amb una cohort suﬁcient, i independent, donades les regles d’eligibilitat. I
optimitzacio´ de l’assaig.
1.1.2 Proteo`mica i l´ınies cel.lulars
Mentre que el DNA conte´ informacio´ completa sobre els plans de la ce`l.lula, i el
mRNA fa la funcio´ de missatger, amb peces d’informacio´ enviades a la maquina`ria
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de la ce`l.lula, les prote¨ınes so´n la part funcional i reﬂecteixen me´s acuradament
el fenotip. Aquesta idea ve reforc¸ada per l’escassa correlacio´ observada entre els
mRNA i les prote¨ınes de la ce`l.lula [Gygi et al., 1999]. Ja que les prote¨ınes repre-
senten un nivell funcional me´s alt que els mRNA, s’espera que la proteo`mica pugui
portar al descobriment de dianes terape`utiques i biomarcadors d’una manera me´s
efectiva que la transcripto`mica ho ha fet. Tanmateix aquest camp encara presenta
un conjunt de reptes a resoldre.
La gran complexitat del proteoma d’un teixit, i l’enorme rang d’abunda`ncies
que s’hi observa, desaconsellen una ana`lisi directa ate`s que la fraccio´ de prote¨ına
que pot estar espec´ıﬁcament relacionada amb una malaltia es condidera gaire be´
negligible. L’alternativa del se`rum, que seria molt apreciada en permetre proves
no invasives, presenta semblants diﬁcultats (ﬁgura 2.4) ja que les 22 prote¨ınes me´s
abundants representen el 99% del seu proteoma [Tirumalai et al., 2003]. Sabent
que els biomarcadors espec´ıﬁcs d’una malaltia donada es produeixen localment,
en el teixit afectat, s’espera que els ﬂuids proximals estiguin enriquits en aquestes
substa`cies, i presentin una complexitat molt menor. Aix´ı el l´ıquid intersticial
representa una font molt interessant de potencials biomarcadors [Rifai et al., 2006].
Per altra banda la disponibilitat de models animals i de l´ınies cel.lulars simpliﬁ-
ca notablement el problema de l’obtencio´ de mostres, particularment en l’estadi de
descobriment de biomarcadors. En concret la facilitat de manipulacio´ i el control
que es te´ sobre les l´ınies cel.lulars facilita l’estudi de les respostes a tractaments,
i a diferents condicions biolo`giques. Per extensio´ dels conceptes anteriors, el con-
junt de prote¨ınes secretades, conegut com a secretoma, que e´s una aproximacio´
al liquid intersticial d’un teixit tumoral, constitueix una font molt va`lida per al
descobriment de biomarcadors tumorals (ﬁgura 2.5).
El treball que aqu´ı es presenta va dirigit a desenvolupar eines i
te`cniques estad´ıstiques que facilitin el descobriment de biomarcadors
tumorals en el secretoma de l´ınies cel.lulars fent e`mfasi en la seva re-
productibilitat.
1.1.3 Espectroscopia de masses
Les prote¨ınes mostren un ventall molt ampli de pesos moleculars i propietats f´ısico-
qu´ımiques, i moltes nome´s so´n solubles sota condicions molt espec´ıﬁques, si e´s que
ho arriben a ser. Aixo` fa que l’ana`lisi directa sobre un proteoma revesteixi una
immensa complexitat, i que sigui forc¸a me´s simple treballar sobre pe`ptids. Les
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unitats constituents de les prote¨ınes. Aquests so´n de pesos moleculars forc¸a me´s
reduits, i generalment solubles sota diverses condicions.
Les te`cniques d’alt rendiment emprades en la identiﬁcacio´ i quantiﬁcacio´ de
prote¨ınes, parteixen d’una mostra que e´s inicialment puriﬁcada per eliminar-ne
els components aliens, i posteriorment digerida amb l’ajut d’enzims (usualment
tripsina) que les degraden a una mescla complexa de pe`ptids. L’avantatge de la
digestio´ amb tripsina esta` en que ataca uns enllac¸os espec´ıﬁcs (l’enllac¸ carboxi-
terminal de l’arginina i la lisina) que posteriorment facilita la identiﬁcacio´ dels
peptids.
El digerit de pe`ptids es sotmet a fraccionament de manera que es poden ob-
tenir diverses submostres de menor complexitat i de propietats f´ısico-qu´ımiques
semblants. El fraccionament pot ser en columnes cromatogra`ﬁques d’exclusio´ mo-
lecular, que permeten classiﬁcar els pe`ptids per pes molecular; en columnes de bes-
canvi io`nic de diversos tipus que permeten la separacio´ en funcio´ del seu cara`cter
io`nic; o en columnes que separen pel seu grau d’hidrofobicitat. Al ﬁnal es te´ un
conjunt de submostres que es passen per una columna cromatogra`ﬁca de nano
ﬂuxe en fase reversa. Aquesta columna es conecta a una agulla de silica o acer
inoxidable de poques micres de diametre intern, que es sotmet a alt voltatge, on
per electro-esprai es produeix un nu´vol de nanogotes carregades que alimenta un
espectro`metre de masses, on es quantiﬁca i s’identiﬁca cada pe`ptid de la mescla.
Aix´ı un experiment de proteo`mica d’alt rendiment (ﬁgura 2.6) consisteix en els
segu¨ents passos [Steen & Mann, 2004]:
1. Aı¨llament i puriﬁcacio´ de la mostra de prote¨ınes.
2. Digestio´ a una complexa mescla de pe`ptids.
3. Separacio´ dels pe`ptids per propietats f´ısico-qu´ımiques.
4. Ionitzacio´ en l’electro-spray a la sortida de la nano-columna.
5. Caracteritzacio´ dels pe`ptids que coelueixen per espectrometria de masses
(MS), mitjanc¸ant la seva relacio´ massa a ca`rrega (m/z) i la intensitat de l’io´.
6. Aı¨llament i posterior fragmentacio´ per MS/MS de cada io´ en els aminoa`cids
constituents per identiﬁcar l’io´ precursor.
Les variables que permeten quantiﬁcar tot el proteoma analitzat so´n, per cada
io´: el temps de retencio´ a la columna, la seva relacio´ massa/ca`rrega, i la sequ¨e`ncia
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d’aminoa`cids constituents. Cada fraccio´ es sotmet a ide`ntica ana`lisi, i un cop
analitzades totes les fraccions s’integren els resultats oferint una quantiﬁcacio´ de
les diverses prote¨ınes constituents de la mostra original [Nesvizhskii et al., 2007].
L’expressio´ LC-MS/MS, indica la connexio´ d’una o diverses etapes croma-
togra`ﬁques, a un equip d’espectroscopia de masses en tandem. Una primera etapa
per separar els ions que co-elueixen per la seva relacio´ ca`rrega/massa (m/z), i una
segona per determinar-ne la sequ¨e`ncia d’aminoa`cids.
La quantiﬁcacio´ pot portar-se a terme ba`sicament per dos me`todes. Per la
senyal d’intensitat dels ions en el primer MS, o pel nombre d’espectres de MS/MS
(SpC) que s’associen a cada prote¨ına. El me`tode seguit en aquest treball e´s
per SpC.
1.1.4 Quantiﬁcacio´ per nombre d’espectres
La quantiﬁcacio´ per SpC ha estat avalada per nombroses publicacions [Old et al.,
2005; Gao et al., 2005; Zybailov et al., 2005]. Una recent revisio´ experta [Lundgren
et al., 2010] considera avantatges i inconvenients en l’u´s d’aquest me`tode, i explora
normalitzacions proposades en la literatura que tenen en compte la longitud de la
prote¨ına o el seu pes molecular en quantiﬁcacio´ absoluta i relativa. El propo`sit
de les normalitzacions esmentades e´s el de tenir en compte que, en igualtat de
condicions, prote¨ınes me´s grans i me´s pesades produiran un nombre d’espectres
major que prote¨ınes me´s curtes o lleugeres.
El descobriment de biomarcadors es basa en la quantiﬁcacio´ relativa d’una ma-
teixa prote¨ına entre dos estats biolo`gics determinats. En aquestes circumsta`ncies
la normalitzacio´ de SpC tenint en compte alguna mesura de complexitat prote`ica
contribueix el mateix a les dues situacions comparades, i per la majoria de me`todes
estad´ıstics no hauria de tenir efecte, tal com ha estat demostrat [Lundgren et al.,
2010]. Els me`todes desenvolupats en aquesta tesi no fan u´s de cap trans-
formacio´ que tingui en compte la complexitat de la prote¨ına.
1.1.5 Expressio´ diferencial sense marcatge qu´ımic
En expressio´ diferencial un me`tode tradicionalment emprat per minimitzar el biaix
en la comparacio´, tant en transcripto`mica [Shalon et al., 1996] com en proteo`mica
[Patel et al., 2009], consisteix en marcar molecularment les mostres. Aixo` permet
mesclar-les el me´s aviat possible en el protocol de preparacio´ i ana`lisi, garantint
que els factors no controlats incideixin de la mateixa forma en totes les mostres
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a comparar. Les marques, o etiquetes, permeten la identiﬁcacio´ posterior de les
prote¨ınes de cada condicio´ biolo`gica. Malgrat els avantatges, aquesta metodolo-
gia presenta certes limitacions. Els punts me´s importants so´n: la incorporacio´
qu´ımica incompleta de les etiquetes, la necessitat de concentracions me´s elevades
en les mostres, me´s baixa sensibilitat en mesurar menys quantitat de cada mostra,
i procediments complexes de preparacio´. Per altra banda el mateix avantatge d’a-
questa metodologia en constitueix una limitacio´. Els experiments estan dedicats
a una u´nica comparacio´, i les dades adquirides dif´ıcilment poden ser reutilitzades
en altres comparacions.
L’ana`lisi de mostres proteiques sense marcar [Zhu et al., 2010] ofereix una
alternativa (ﬁgura 2.10) me´s ﬂexible i eﬁcient, sempre que es puguin evitar biaixos
en la comparacio´. Aixo` exigeix experiments dissenyats i planiﬁcats amb cura. El
major risc e´s el de factors no controlats que afectin de manera diversa una condicio´
respecte l’altre.
L’objectiu d’aquesta tesi e´s l’ana`lisi d’expressio´ diferencial en secre-
tomes de l´ınies cel.lulars per LC-MS/MS sense marcar.
1.1.6 Infere`ncia amb SpC
Les dades que s’obtenen d’un experiment de LC-MS/MS consisteixen en una ma-
triu d’expressio´ on cada columna correspon a una mostra i cada ﬁla a una prote¨ına
identiﬁcada. Els valors en les cel.les so´n els SpC observats. En aquesta matriu d’-
expressio´ hi poden haver diverses re`pliques te`cniques i/o biolo`giques de diverses
condicions biome`diques. Aquestes dades so´n la base del BD, que consisteix en tro-
bar prote¨ınes diferencialment expressades en termes estad´ıstics entre les condicions
biome`diques d’intere`s. El que segueix descriu els principals me`todes estad´ıstics em-
prats en la comparacio´ de comptatges, per acabar amb una revisio´ de l’estat de
l’art en proteo`mica comparativa per SpC.
Taules de continge`ncia
En considerar una sola de les prote¨ınes identiﬁcades, la manera me´s simple de
representar les dades e´s en forma d’una taula de continge`ncia com en la taula 1.1.
La primera ﬁla ens do´na els SpC observats per aquesta prote¨ına en cada condicio´.
La segona ﬁla ens do´na els SpC observats per la resta de prote¨ınes identiﬁcades.
Els SpC totals, a la tercera ﬁla, donen mesura de la quantitat total de prote¨ına de
cada condicio´.
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Taula 1.1: Taula de continge`ncia
Cond1 Cond2 . . . Condc Total
SpC prote¨ına d’intere`s x11 x12 . . . x1c x1o
SpC altres prote¨ınes x21 x22 . . . x2c x2o
SpC totals en la mostra xo1 xo2 . . . xoc n
Els me`todes estad´ıstics de directa aplicacio´ so´n el test exacte de Fisher, el test
χ2 de Pearson, o el test de rao´ de versemblanc¸a G2 [Agresti, 2002]. El test de
Fisher s’aplica a taules 2x2, i s’anomena exacte perque` se’n coneix la distribucio´
i no depe`n de propietats assimpto`tiques. El Test de Pearson avalua la hipo`tesi
nul.la d’independe`ncia, que per mostres multinomials independents correspon a la
homogene¨ıtat de resposta entre les condicions comparades. El test G2 avalua un
estad´ıstic de rao´ de versemblanc¸a comparant el model nul contra el saturat. Els
dos estad´ıstics X2 i G2 so´n assimpto`ticament equivalents.
Transformacio´ de SpC
Quan es disposi d’un nombre re`pliques per condicio´ que permeti una suﬁcient
estimacio´ de la varia`ncia, un me`tode alternatiu e´s el d’emprar una transformacio´
del nombre d’espectres que possibiliti usar te`cniques basades en la distribucio´
normal. En condicions ideals els comptatges poden descriure’s per una distribucio´
de Poisson, on la varia`ncia e´s igual a la mitjana. Amb aquesta mena de comptatges
la varia`ncia s’estabilitza amb transformacions del tipus x′ =
√
x o x′ =
√
x +√
x+ 1 [Kutner et al., 2005]. Sobre aquests valors transformats pot emprar-se el
test de t. L’aproximacio´ e´s poc exacte per a valors molt baixos d’expressio´.
Models lineals generalitzats
Una solucio´ me´s general, que a me´s permet la introduccio´ de me´s d’un factor i de
covariables, e´s la dels models lineals generalitzats (GLM) [Agresti, 2002]. Aquests
so´n aplicables sobre dades que puguin modelar-se segons una distribucio´ de la
famı´lia exponencial. Aquestes famı´lia presenta una funcio´ densitat de probabilitat
factoritzable com en l’equacio´ 1.1
f(yi; θi) = a(θi)b(yi)exp[yiQ(θi)] (1.1)
Exemples en so´n la distribucio´ de Poisson o la binomial negativa. Un GLM
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s’especiﬁca amb tres components: i) Una variable aleato`ria de resposta Y , i la
seva distribucio´ de probabilitat. ii) Una component sistema`tica donada per una
combinacio´ lineal de variables predictores. I iii) Una funcio´ d’enllac¸ que relaciona
E[Y ] amb el predictor lineal. En el nostre cas la funcio´ d’enllac¸ e´s el logaritme





La distribucio´ de Poisson queda deﬁnida per un sol para`metre μ que equival a
la mitjana i a la varia`ncia de la distribucio´:
μ = E[X] = V ar[X] (1.3)
La distribucio´ binomial negativa queda deﬁnida amb dos para`metres μ i φ.
Com en la distribucio´ de Poisson μ equival a la mitjana de la distribucio´, mentre
que la varia`ncia e´s una funcio´ d’ambdo´s para`metres:
V ar(X) = μ+ φμ2 (1.4)
El model de Poisson e´s aplicable en aquells casos en que l’u´nica font de variabi-
litat e´s la pro`pia del mostreig. Mentre que el model basat en la binomial negativa
pot incorporar a me´s la variabilitat t´ıpica entre individus o espe`cimens. De fet la
binomial negativa equival a un model mixte de Poisson on μ es distribueix segons
una gamma.
Una extensio´ dels GLM e´s la quasiversemblanc¸a, on l’ajust es fa segons un
model de Poisson, pero` la infere`ncia te´ en compte una funcio´ de varia`ncia com en
l’equacio´ 1.5, on el coeﬁcient de dispersio´ ψ s’estima a partir de les dades.
V ar(Y ) = ψμi (1.5)
Aquest model tambe´ pot explicar fonts addicionals de varia`ncia com la varia-
bilitat biolo`gica entre individus, cultius o espe`cimens.
Estat de l’art en proteo`mica comparativa per SpC
Tots els me`todes descrits me´s amunt han estat emprats en proteo`mica diferencial.
Els primers a explorar-se varen ser els basats en taules de continge`ncia, en el test
de t, o en varacions de me`todes desenvolupats espec´ıﬁcament per a microarrays,
SAGE o DGE [Zybailov et al., 2006; Zhang et al., 2006; Pavelka et al., 2008].
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L’estat de l’art actual es basa en la implementacio´ de GLMs. Be´ de models d’efectes
mixtes [Choi et al., 2008], de quasiversemblanc¸a [Li et al., 2010], o de la binomial
negativa [Leitch et al., 2012]. L’objectiu de tots aquests models e´s el de tenir en
compte la variabilitat biolo`gica de les mostres, causant de la sobredispersi, s a dir
d’una variancia major que la mitjana. Aquests me`todes han anat proposant-se
paral.lelament al desenvolupament de la tesi, i com evidencia el darrer treball citat
encara hi ha molt potencial de recerca en el camp.
La solucio´ adoptada en la tesi e´s la dels GLM.
1.1.7 Llic¸ons en el descobriment de biomarcadors
La reproductibilitat en les llistes de biomarcadors e´s el punt me´s crucial en BD. En
aquest sentit resulta molt u´til considerar l’experie`ncia adquirida en gaire be´ vint
anys de transcripto`mica, en beneﬁci d’altres o`miques me´s joves, i en particular de la
proteo`mica. En aquest apartat es presenten algunes de les pricipals llic¸ons apreses
en BD, tant en transcripto`mica com en proteo`mica. Aquestes llic¸ons porten als
objectius de la tesi.
Normalitzacio´
La normalitzacio´ s’ente´n com un procediment per eliminar difere`ncies sistema`tiques
de naturalesa te`cnica entre les mostres. Ate`s que de cada mostra es mesura la ma-
teixa quantitat de substa`ncia, el procediment me´s este`s consisteix a referir els SpC
de cada prote¨ına al total de SpC observats en la mostra. En el context dels mo-
dels GLM aquesta normalitzacio´ s’incorpora al model mitjanc¸ant un terme d’oﬀset







= α + βx
log(μ) = log(size) + α + βx (1.6)
on μ e´s l’expressio´ esperada d’una prote¨ına donada, size e´s el factor de normalitza-
cio´, i α i β so´n els para`metres del model, amb x igual a 0 per la condicio´ de control,
o a 1 per la condicio´ de tractament. El terme log(size) e´s l’oﬀset en aquest cas.
Aquest model admet la inclusio´ d’altres factors o covariables. La formulacio´ del
model e´s independent de la distribucio´ subjacent.
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En termes biolo`gics aquesta normalitzacio´ es basa a me´s en la suposicio´ que les
ce`l.lules produeixen la mateixa quantitat global de prote¨ına en les dues condicci-
ons que es comparen. Aquesta suposicio´ pot acceptar-se en general quan
s’analitzen mostres de llisats cel.lulars, pero` resulta me´s qu¨estionable
quan s’analitzen secretomes de l´ınies cel.lulars. Aquest tema crucial
tambe´ s’investiga i es resol en la tesi, proposant un esquema espec´ıﬁc
de normalitzacio´ basat en oﬀsets .
P-valors i mida de l’efecte
En els inicis dels microarrays el BD es basava simplement en els FC observats.
Paulatinament es van a anar introduint me`todes estad´ıstics de creixent soﬁstiﬁca-
cio´, i ajustaments de multitest en els p-valors, amb control del FDR [Allison et al.,
2006]. Els resultats d’un estudi de microarrays es donaven en una llista de gens
diferencialment expressats en ordre creixent de p-valor. Els gens del capdemunt
de la llista se solen considerar els me´s signiﬁcatius.
En aquest context, amb diferents plataformes de microarrays comercialment
disponibles, i amb les grans expectatives que la introduccio´ dels microarrays van
despertar, aviat es va evidenciar que no es podien reproduir els resultats d’alguns
biomarcadors que s’havien publicat amb altes taxes de sensibilitat i especiﬁcitat.
D’entre els projectes que es van endegar per estudiar els factors que afectaven
la reproductibilitat dels resultats per microarrays destaca el MicroArray Quality
Control Consortium [Shi et al., 2006], format per membres de les autoritats re-
guladores (FDA), autoritats acade`miques, i institucions comercials. El nu´mero
de setembre de 2006 de Nature Biotechnology va estar completament dedicat als
resultats de l’estudi MAQC-I. Les seves recomanacions, per tal d’obtenir llistes
reproductibles de gens diferencialment expressats, me´s enlla` d’emprar acurats dis-
senys experimentals, i de reco`rrer a transformacions apropiades de dades, es basa-
ven en limitar el nombre de transcrits identiﬁcats com a diferencialment expressats,
i amb ordenar-los atenent al FC amb un llindar de p-valor no massa astringent.
Aquests resultats varen ser qu¨estionats [Chen et al., 2007] i posteriorment conﬁr-
mats comparant diferents me`todes de seleccio´ de gens i amb simulacions [Shi et al.,
2008].
Resumint, els gens del capdemunt de la lista han de ser no els de major sig-
niﬁcacio´ estad´ıstica, si no els que mostren major efecte amb un p-valor ajustat
raonable.
Aquesta llic¸o´ s’implementa en el treball en forma d’un ﬁltre post-test
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que marca les prote¨ınes amb poca senyal i baix efecte com d’escassa
reproductibilitat malgrat el seu baix p-valor. La llista de prote¨ınes
diferencialment expressades s’ordena per p-valor amb el corresponent
indicador.
Efectes batch
Les conclusions de l’estudi MAQC-I estan directament relacionades amb el pro-
blema de molts-gens-poques-re`pliques. Aixo` suggereix que augmentant el nombre
de re`pliques augmentara` la pote`ncia i millorara` la reproductibilitat. Malhaura-
dament s’ha observat que augmentant el nombre de re`pliques augmenta tambe´ la
possibilitat d’introduir biaix (Speed T. en [Scherer, 2009]). Quan els experiments
es recullen durant un periode llarg de temps el biaix pot resultar inevitable. Aixo`
esta` relacionat amb els anomenats efectes batch. Malgrat que un bon disseny ex-
perimental i l’u´s de randomitzacions i blocs en cada pas de tot el proce´s, des de
la recollida de mostres ﬁns l’ana`lisi ﬁnal, puguin reduir molt els efectes de varia-
bles no controlades, els efectes batch es mostren ubics i inevitables en les o`miques
[Ransohoﬀ, 2005a; Scherer, 2009; Leek et al., 2010; Auer & Doerge, 2010; Schloss
et al., 2011; Valsesia et al., 2013].
Els efectes batch es deﬁneixen com a sistema`tics en contraposicio´ al soroll te`cnic
o experimental, que e´s de natura aleato`ria. Degut a la seva natura sistema`tica la
pitjor manifestacio´ dels efectes batch s’observa quan les mostres tractament es
preparen i analitzen separadament de les mostres control, en lots diferents o en
temps diferents. Les difere`ncies que s’observin estaran confoses entre l’efecte del
tractament i dels factors no controlats que puguin inﬂuir. Aquesta ha estat la
causa me´s frequ¨ent i estrepitosa de fracassos en BD [Baggerly et al., 2004, 2005;
Ransohoﬀ, 2005b; Baggerly et al., 2008; Baggerly & Coombes, 2009]. Una ma-
nifestacio´ menys drama`tica s’observa quan les mostres s’han analitzat de manera
balancejada en les condicions a comparar, pero` en moments espaiats en el temps.
Aixo` causa un augment de la variabilitat intraclasse reduint la pote`ncia dels tests.
La prese`ncia d’efectes batch es pot visualitzar amb l’u´s de te`cniques multi-
dimensionals com l’ana`lisi en components principals (PCA), la descomposicio´ en
valors singulars (SVD), o el clustering jera`rquic (HC). Idealment les mostres han
d’agrupar-se per condicio´ biolo`gica. La prese`ncia d’efectes batch es manifesta quan
les mostres s’agrupen pel moment en que es van recollir o pel moment en que es
van tractar i analitzar, en comptes de per la seva condicio´ biolo`gica (veure ﬁgura
2.11).
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Com a resposta a aquesta llic¸o´ s’han implementat eines multidimen-
sionals de visualitzacio´ en un paquet R/Bioconductor, i s’ha dissenyat
una interf´ıcie gra`ﬁca que facilita l’ana`lisi explorato`ria de dades de LC-
MS/MS basades en SpC per evidenciar la prese`ncia de valors extrems
o d’efectes batch. Per altre banda els models GLM proposats i imple-
mentats en un altre paquet R/Bioconductor permeten portar a terme la
infere`ncia tenint en compte la prese`ncia dels efectes batch eventualment
detectats en l’ana`lisi explorato`ria pre`via.
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1.2 Objectius
L’establiment d’un nou laboratori de biomarcadors tumorals a l’Institut d’Onco-
logia de la Vall d’Hebron (VHIO) ha ofert l’oportunitat de desenvolupar eines
d’ana`lisi de dades en proteo`mica comparativa, i contribuir a posar en valor l’-
experie`ncia adquirida en el tractament de dades o`miques de microarrays durant
me´s d’una de`cada, traslladant part de les llic¸ons apreses al camp de la poteo`mica
comparativa. En aquest sentit, els objectius d’aquesta tesi so´n la implementacio´
d’eines i me`todes espec´ıﬁcament dirigits a:
• Ana`lisi de dades d’experiments de proteo`mica diferencial sense marcatge
qu´ımic i basats en el nombre observat d’espectres de pe`ptids.
• Avaluacio´ de la qualitat d’un conjunt de dades en termes de deteccio´ de
valors extrems, i de la inﬂue`ncia de factors no controlats.
• Modelitzacio´ i normalitzacio´ de dades de secretomes de l´ınies cel.lulars.
• Millora en la reproductibilitat de les llistes de prote¨ınes diferencialment ex-
pressades.
• Produir paquets de R amb les eines desenvolupades.
• Produir interf´ıcies gra`ﬁques que facilitin l’u´s de les eines proposades.
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1.3 Resultats
Totes les publicacions presentades en la tesi han estat sotmeses a revistes interna-
cionals amb avaluacio´ d’experts.
El sofware desenvolupat ha estat encapsulat en paquets R sotmesos a Biocon-
ductor, i en dues interf´ıcies gra`ﬁques disponibles a GitHub.
Tot seguit es presenta una llista de les publicacions amb els abstracts cor-
responents, i una breu descripcio´ dels paquets R i les respectives interf´ıcies. A
continuacio´ s’exposa una discussio´ general, i es donen les conclusions de la tesi
amb les contribucions al camp estudiat. Per acabar s’inclou una llista d’altres pu-
blicacions de l’autor en el camp de la bioestad´ıstica/bioinforma`tica no relacionades
amb la tesi pero` realitzades durant el seu desenvolupament.
1.4 Articles de la tesi
1. La correccio´ d’eﬀectes batch millora la sensibilitat dels tests en proteo`mica com-
parativa basada en comptatge d’espectres.
Batch eﬀects correction improves the sensitivity of signiﬁcance tests in spec-
tral counting-based comparative discovery proteomics.
Gregori J, Villarreal L, Me´ndez O, Sa´nchez A, Baselga J, Villanueva J.
J Proteomics. 2012 Jul 16; 75(13):3938-51. doi: 10.1016/j.jprot.2012.05.005.
Epub 2012 May 12.
Factor d’impacte: 4.1
RESUM
La proteo`mica per shotgun ha esdevingut la te`cnica esta`ndar per a la mesu-
ra a gran escala d’abunda`ncia de prote¨ınes en mostres biolo`giques. Malgrat
que la proteo`mica quantitativa ha emprat usualment te`cniques de marcatge
molecular, la quantiﬁcacio´ sense marcadors ofereix avantatges considerables.
Entre elles: i) Evitar els procediments de marcatge. ii) No presentar limi-
tacio´ en el nombre de mostres a comparar. I iii) Augment de la sensibilitat
en la deteccio´ de prote¨ınes. Tanmateix ate`s que les mostres so´n tractades i
analitzades de forma separada, el disseny experimental esdeve´ cr´ıtic. L’ex-
ploracio´ de la quantiﬁcacio´ per nombre d’espectres que es presenta en aquest
treball recull evide`ncia experimental de la inﬂue`ncia dels eﬀectes batch en
proteo`mica comparativa. Aquests eﬀectes, demostrats amb experiments amb
mescles controlades, interfereixen clarament amb el senyal biolo`gic. Per tal
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de minimitzar la interfere`ncia dels eﬀectes batch es proposa i implemen-
ta una correccio´ estad´ıstica. Els resultats demostren que aquests efectes
es poden atenuar emprant un disseny experimental adequat. La correccio´
implementada porta a un augment substancial de la sensibilitat dels tests.
L’aplicabilitat de la correccio´ proposada es mostra sobre dos projectes de des-
cobriment de biomarcadors amb secretomes de ca`ncer. El me`tode proposat
permet millorar el disseny i l’execucio´ de projectes de proteo`mica compara-
tiva, i contribueix a evitar falses conclusions en el proce´s de descobriment de
biomarcadors en proteo`mica.
2. Un ﬁltre de mida de l’efecte millora la reproductibilitat en proteo`mica compara-
tiva basada en comptatge d’espectres.
An eﬀect size ﬁlter improves the reproducibility in spectral counting-based
comparative proteomics.
Gregori J, Villarreal L, Sa´nchez A, Baselga J, Villanueva J.
J Proteomics. 2013 Dec 16; 95:55-65.
doi: 10.1016/j.jprot.2013.05.030. Epub 2013 Jun 11
Factor d’impacte: 4.1
RESUM
La comunitat en el camp dels microarrays ha demostrat que la baixa repro-
ductibilitat observada en alguns estudis de descobriment de biomarcadors
en expressio´ geno`mica e´s parcialment deguda a basar les llistes de gens di-
ferencialment expressats exclusivament en p-valors. Les seves conclusions
recomanen complementar el llindar de p-valor amb l’u´s de criteris d’efecte.
La intencio´ d’aquest treball ha estat avaluar la inﬂue`ncia d’un ﬁltre per mida
de l’efecte i intensitat del senyal en l’ana`lisi de proteo`mica comparativa ba-
sada en nombre d’espectres. Els resultats han provat que el ﬁltre augmenta
el nombre de positius certs i disminueix el nombre de falsos positius en el
seu conjunt. Aquests resultats s’han conﬁrmat amb conjunts de dades si-
mulades, amb augment progressiu en la fraccio´ de prote¨ınes diferencialment
expressades. Els resultats suggereixen que relaxant el llindar de p-valor i
emprant un ﬁltre posterior als test, basat en llindars en el nivell del senyal
i en la mida de l’efecte, pot augmentar la reproductibilitat dels resultats.
En base als resultats d’aquest treball, es recomana com a pra`ctica general
emprar un ﬁltre exigint un senyal mı´nim entre 2 i 4 SpC en la condicio´ me´s
abundant, i un efecte no inferior a un LogFC en valor absolut de 0.8. La
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implementacio´ d’aquests ﬁltres pot millorar els resultats en el descobriment
de biomarcadors a l’assegurar una major reproductibilitat entre laboratoris
independents i diferents plataformes de MS.
3. Millora en el valor biolo`gic de la proteo`mica de secretomes, vinculant la prolife-
raci cel.lular del tumor i la secrecio´ de prote¨ınes.
Enhancing the Biological Relevance of Secretome-based Proteomics by Linking
Tumor Cell Proliferation and Protein Secretion.
Gregori J., Me´ndez O., Katsila T., Pujals M., Salvans C., Villarreal L., Ar-
ribas J., Tabernero J., Sa´nchez A., Villanueva J.
Sotme`s a J. of Proteome Research, pendent de publicacio´.
RESUM
La determinacio´ del perﬁl dels secretomes ha esdevingut una metodologia
u´til en el descobriment de biomarcadors tumorals secretats. Els secretomes
so´n proteomes molt dina`mics que contenen prote¨ınes directament involucra-
des en diferents aspectes de la tumoroge`nesi. Degut a la seva naturalesa
dina`mica es va formular la hipo`tesi que algunes pertorbacions cel.lulars po-
dien no nome´s afectar la composicio´ del secretoma si no tambe´ canviar la
taxa de secrecio´ cel.lular. De resultar certa, aquesta observacio´ seria molt re-
llevant en el descobriment de biomarcadors, ja que la unitat biolo`gica sobre
la que es cerca la comparativa e´s la ce`l.lula. En aquest treball s’ha desenvo-
lupat i implementat un model que incorpora una normalitzacio´ que permet
referir els resultats a la quantitat de prote¨ına secretada per ce`l.lula. El model






+ log(size) + α + βx+ γz (1.7)
on Q e´s la quantitat de prote¨ına secretada per n ce`l.lules, en una mostra amb
size SpC totals, X e´s el factor tractament, i Z un eventual factor per blocs.
S’han detectat difere`ncies substancials en la quantitat global de prote¨ına se-
cretada entre ce`l.lules sotmeses a diferents pertorbacions biolo`giques, i tambe´
entre l´ınies cel.lulars en el seu estat basal. L’aplicacio´ del model a dos es-
cenaris biolo`gics diferents amb ce`l.lules tumorals ha mostrat un fort efec-
te sobre la llista de prote¨ınes diferencialment secretades. En aquest sentit
s’ha vist que efectors de la trancisio´ epitelial a mesenquimal nome´s resul-
ten estad´ısticament signiﬁcatius quan s’aplica el model descrit. L’estudi ha
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perme`s tambe´ individualitzar altres prote¨ınes encara no descrites en l’esmen-
tada trancisio´ que poden resultar d’intere`s com a biomarcadors. Finalment
l’estudi suggereix que la taxa de secrecio´ global de prote¨ınes en ce`l.lules tu-
morals esta` relacionada amb el seu estat de proliferacio´ cel.lular. El treball
conﬁrma la hipo`tesi inicial i mostra que la naturalesa dina`mica dels secre-
tomes pot esbiaixar els resultats en el descobriment de biomarcadors de no
emprar un model adequat. Des del punt de vista oncolo`gic el vincle entre se-
crecio´ proteica i proliferacio´ cel.lular suggereix que els tumors de creixement
lent poden ser susceptibles de majors taxes de secrecio´, i en consequ¨e`ncia
contribuir en major grau a la senyalitzacio´ paracrina.
4. La secrecio´ no convencional e´s un contribuent major en els secretomes de l´ınies
cel.lulars de ca`ncer.
Unconventional secretion is a major contributor of cancer cell line secreto-
mes.
Villarreal L, Me´ndez O, Salvans C, Gregori J, Baselga J, Villanueva J.
Mol Cell Proteomics. 2013 May; 12(5):1046-60.
doi: 10.1074/mcp.M112.021618. Epub 2012 Dec 26.
Factor d’impacte: 7.4
RESUM
Un repte per aconseguir una gestio´ o`ptima del ca`ncer e´s el descobriment
de biomarcadors secretats que representin l’estat de la malaltia i es puguin
mesurar de forma no invasiva. Degut a la problema`tica que planteja l’ana`lisi
del proteoma del plasma, s’ha proposat el secretoma com a font alternativa
de marcadors, ja que pot estar enriquit en prote¨ınes secretades rellevants
de la malaltia. Tanmateix, l’ana`lisi del secretoma planteja tambe´ els seus
reptes. En particular distingir les prote¨ınes realment secretades. En aquest
treball s’han estudiat dos dels principals reptes en l’ana`lisi de secretomes
en proteo`mica comparativa. En primer lloc, s’ha portat a terme un estudi
cine`tic en el que s’ha analitzat el secretoma i el llisat cel.lular per monitoritzar
la viabilitat cel.lular durant la produccio´ de secretoma. S’ha determinat que
un grup de prote¨ınes secretades es correlaciona be´ amb l’apoptosi indu¨ıda
en el periode d’inanicio´ per se`rum, i que pot emprar-se com a indicador
intern de viabilitat cel.lular. En segon lloc, s’han determinat les interfere`ncies
causades pel necessari u´s de se`rum en el cultiu cel.lular. L’ana`lisi proteo`mica
comparativa entre l´ınies cel.lulars marcades amb SILAC ha mostrat un cert
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nombre de falsos positius que provenen del se`rum, i que diverses prote¨ınes
es troben tant en el serum com en el secretoma de ce`l.lules tumorals.
Per altra banda un estudi minucio`s de la metodologia d’obtencio´ de secreto-
ma ha revelat que sota condicions experimentals o`ptimes hi ha una fraccio´
substancial de prote¨ınes que so´n secretades per mecanismes no convencionals.
Finalment s’ha mostrat que algunes prote¨ınes nuclears detectades en el secre-
toma canvien de localitzacio´ cel.lular en tumors de mama, suggerint que les
ce`l.lules tumorals usen una secrecio´ no convencional durant la tumoroge`nesi.
La secrecio´ no convencional de prote¨ınes en l’espai extracel.lular exposa un
nou nivell de regulacio´ geno`mica post-translacional que pot constituir una
font potencial de biomarcadors tumorals i de dianes terape`utiques.
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pp.msms.data preprocessat de dades per convertir NAs en
0 i eliminar les ﬁles amb tot zeros.
gene.table extreure els s´ımbols de gen de la descripcio´
de prote¨ına.
count.stats estad´ıstics de SpC i nombre de prote¨ınes per
mostra.
counts.pca ana`lisi de components principals de la matriu
de SpC.
counts.hc dendrograma del clustering jera`rquic de les
mostres.
norm.counts normalitzacio´ de la matriu de SpC.
counts.heatmap heatmap de la matriu de SpC.
disp.estimates ana`lisi de dispersio´ residual.
spc.barplots gra`ﬁc de barres dels divisors de normalitzacio´
relatius.
spc.boxplots gra`ﬁc de caixes mostrant la distribucio´ de
SpC per mostra.
spc.densityplots gra`ﬁc de densitat mostrant la distribucio´ de
SpC per mostra.
filter.flags marques llo`giques per les prote¨ınes segons
llindars de senyal i variabilitat.
bacth.neutralize correccio´ d’efectes batch en la matriu de SpC.




El software ha estat desenvolupat en el llenguatge i entorn R [R Core Team, 2012].
S’han produit dos paquets R amb el codi desenvolupat durant els treballs que han
portat a la publicacio´ dels articles esmentats me´s amunt. Aquests paquets han
estat adaptats a la infraestructura de Bioconductor [Gentleman et al., 2004], i
adaptats espec´ıﬁcament per treballar amb insta`ncies de la classe S4 MSnSet deﬁ-
nida en el paquet MSnbase [Gatto & Lilley, 2012].
− msmsEDA recull les funcions emprades en l’ana`lisi explorato`ria de matrius
d’expressio´ amb SpC.
− msmsTests ofereix funcions u´tils en infere`ncia sobre matrius d’expressio´ amb
SpC, basades en models GLM.
Les funcions per l’ana`lisi explorato`ria de dades (EDA) permeten la identiﬁcacio´
de valors extrems, efectes batch, o factors de confusio´. Qualsevol estudi de BD
hauria de comenc¸ar sistema`ticament per un EDA en profunditat per validar les
mostres i el model que s’usara` posteriorment en l’estudi. Les principals funcions
del paquet msmsEDA es llisten en la taula 1.2.
El proce´s de BD es porta a terme per l’aplicacio´ del mateix model i test sobre
cada ﬁla de la matriu d’expressio´. El model general considerat en les funcions del
paquet msmsTests e´s el de l’equacio´ 1.7. Es disposa d’una funcio´ per el GLM basat
en la distribucio´ de Poisson, d’una altra basada en la quasiversemblanc¸a, i d’una
altra basada en la binomial negativa. Per la Poisson i la quasiversemblanc¸a el test
e´s el de la rao´ de versemblances entre el model alternatiu i el null. Per la binomial
negativa s’usa l’aproximacio´ implementada en el paquet edgeR [Robinson et al.,
2010]. Les principals funcions d’aquest paquet es llisten en la taula 1.3.
Ambdo´s paquets inclouen funcions que ajuden en la interpretacio´ dels resultats.
Disponibilitat
Els paquets s’han integrat en el projecte Bioconductor [Gentleman et al., 2004] i
usen la classe S4 MSnSet en el paquet MSnbase [Gatto & Lilley, 2012].




msms.glm.pois Model GLM de Poisson
msms.glm.qlll Model GLM de quasiversemblanc¸a
msms.edgeR Model de la binomial negativa del paquet ed-
geR
pval.by.fc Taula creuada de frequ¨e`ncia de prote¨ınes per
p-valors en blocs de LogFC
test.results Ajustament multitest de p-valors amb con-
trol de FDR, i ﬁltre post-test per marcar els
DEPs me´s reproductibles.
res.volcanoplot Volcanplot dels resultats.
Taula 1.3: Funcions en el paquet msmsTests.
Documentacio´
Els manuals dels paquets i tutorials en forma de vignettes estan disponibles on-line
a http://www.bioconductor.org.
− Manual de msmsEDA
http://www.bioconductor.org/packages/2.13/bioc/manuals/
msmsEDA/man/msmsEDA.pdf
− Vignette de msmsEDA: Analisi exploratory de dades de LC-MS/MS.
http://www.bioconductor.org/packages/release/bioc/vignettes/
msmsEDA/inst/doc/msmsData-Vignette.pdf
− Manual de msmsTests
http://www.bioconductor.org/packages/2.13/bioc/manuals/
msmsTests/man/msmsTests.pdf
− Vignette de msmsTests: Filtres post test per millorar la reproductibilitat.
http://www.bioconductor.org/packages/2.13/bioc/vignettes/
msmsTests/inst/doc/msmsTests-Vignette.pdf
− Vignette de msmsTests: Disseny per bocks per compensar efectes batch.
http://www.bioconductor.org/packages/2.13/bioc/vignettes/
msmsTests/inst/doc/msmsTests-Vignette2.pdf
S’adjunten a la tesi un tutorial, els manuals, i les vignettes dels dos paquets.
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1.5.2 Interf´ıcies gra`ﬁques
S’han desenvolupat dues interf´ıcies gra`ﬁques (GUI) per facilitar els ca`lculs rutinaris
en un entorn de laboratori, i per acostar les solucions incorporades en els paquets
descrits als investigadors en el camp de la proteo`mica que no disposin d’habilitats
de programacio´. Els GUI s’han desenvolupat sobre les funcions dels dos paquets
descrits, i amb l’ajut de la infraestructura proporcionada pels paquets gWidgets i
RGtk2 [Verzani, 2012; Lawrence & Verzani, 2012; Lawrence & Temple Lang, 2010].
− msmsEDA GUI
Proporciona una ana`lisi explorato`ria completa d’un experiment LC-MS/MS
donats dos ﬁtxers. El ﬁtxer de descripcio´ de les mostres (targets), amb iden-
tiﬁcadors de mostra, etiquetes, i eventuals factors (divisors) de normalitzacio´.
I un ﬁtxer amb la matriu d’expressio´ en SpC, i descriptors de les prote¨ınes
identiﬁcades.
Mitjanc¸ant gra`ﬁcs de caixes i de densitat de distribucio´ de SpC de cada
mostra, i gra`ﬁcs de barres dels valors relatius dels factors de normalitzacio´
per mostra, es porta a terme una avaluacio´ de la qualitat del conjunt de
dades de l’experiment. La matriu d’expressio´ per SpC s’analitza per les
te`cniques de PCA, HC i heatmaps. I aquesta ana`lisi es fa sobre la matriu de
SpC sense tractar, sobre la matriu de SpC normalitzada, i si s’escau sobre
la matriu de SpC normalitzada i corregida d’eﬀectes batch. La distribucio´
de prote¨ınes informatives segons el factor principal es visualitza a cada pas
del tractament de dades. Finalment s’explora la distribucio´ de valors de
coeﬁcient de dispersio´ residual. El proce´s genera un conjunt de ﬁtxers de
text amb resultats i gra`ﬁcs que permeten visualitzar i avaluar els diferents
passos de l’EDA. Tambe´ es genera un ﬁtxer html que serveix com a ı´ndex de
tots els ﬁtxers generats, amb noms, descripcio´ i vincles a cadascun.
− msmsTests GUI
Donats els ﬁtxers de descripcio´ de mostres i de matriu de SpC, com en l’altra
interf´ıcie, proporciona una gran ﬂexibilitat en BD amb controls en el GUI que
permeten escollir el me`tode de normalitzacio´, el test estad´ıstic, el me`tode de
correccio´ de p-valors amb control de la FDR, el llindar de signiﬁca`ncia, i els
llindars de senyal i mida d’efecte en el ﬁltre post-test. El control de sortida en
la interf´ıcie mostra el desenvolupament dels ca`lculs, i els principals resultats.
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Es generen un conjunt de ﬁtxers de text i pdf amb gra`ﬁcs, amb resultats
intermedis i la llista ﬁnal.
Disponibilitat i documentacio´
Les iterf´ıcies i la seva documentacio´ estan disponibles on-line a GitHub.com
msmsEDA GUI https://github.com/JosepGregori/msmsEDA GUI repos
msmsTests GUI https://github.com/JosepGregori/msmsTests GUI repos
S’adjunten a la tesi les guies d’usuari de les dues interf´ıcies.
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1.6 Discussio´ general
Aquest treball s’ha concentrat en tres aspectes rellevants del proce´s de descobri-
ment de biomarcadors (BD): efectes batch, reproductibilitat, i el disseny d’un
model per la comparacio´ de secretomes en l´ınies cel.lulars entre dues condicions
biolo`giques cel.lula-a-cel.lula.
Hem estudiat la incide`ncia dels efecte batch [Scherer, 2009] en proteo`mica com-
parativa sense marcatge basada en SpC, i hem ﬁxat la ﬁnestra de temps me´s estreta
en la que els assajos de LC-MS/MS estan afectats de manera equivalent pels factors
no controlats en un sol dia d’adquisicio´ de dades [Gregori et al., 2012].
La prese`ncia d’efectes batch s’ha determinat amb te`cniques multidimensionals
com l’ana`lisi de components principals (PCA) o el clustering jera`rquic (HC). Lla-
vors hem estudiat me`todes de correccio´ d’aquests efectes [Chen et al., 2011] en
experiments balancejats en les condicions a comparar, i hem trobat que el millor
me`tode e´s una correccio´ d’escala implementada en un GLM amb funcio´ d’enllac¸
logar´ıtmica que incorpora un factor per blocs [Quinn & Keough, 2002] agrupant
cada lot de mostres.
Basant-nos en els aspectes conceptuals de les recomanacions de l’estudi MAQC-
I [Shi et al., 2008], hem estudiat els avantatges d’emprar un ﬁltre post-test per
nivell de senyal i mida de l’efecte en la millora de la reproductibilitat de biomar-
cadors descoberts per LC-MS/MS lliure de marcatge amb SpC. Hem determinat
que aquests ﬁltres poden millorar el nombre de positius certs (TP), tot i restringir
el nombre de falsos positius (FP), relaxant el llindar de signiﬁca`ncia. Hem vist
tambe´ que aquest tipus de ﬁltre ofereix l’avantatge addicional de millorar el sola-
pament entre llistes de prote¨ınes declarades com diferencialment expressades per
tests diferents. Ambdo´s factors contribuixen a millorar la reproductibilitat dels
resultats [Gregori et al., 2013].
Partint de la hipo`tesi de taxa de secrecio´ variable en l´ınies cel.lulars de ca`ncer
sota diferents pertorbacions biolo`giques, hem desenvolupat un model GLM per
comparacions de secretoma cel.lula-a-cel.lula lliures de biaix [Gregori et al., 2014]
(veure seccio´ 4.3). Aquest model incorpora: i) una normalitzacio´ de mostra pel
nombre total de SpC, ii) la normalitzacio´ cel.lula-a-cel.lula emprant la taxa de
secrecio´ observada en cada condicio´, iii) el factor de tractament rellevant per la
comparacio´, i iv) factors per blocs.
El codi R produit en el desenvolupament d’aquests estudis s’ha estructurat en
funcions d’u´s general i s’ha encapsulat en dos paquets a Bioconductor [Gentleman
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et al., 2004]. Un paquet per l’ana`lisi explorato`ria de dades per detectar valors
extrems, efectes batch o la prese`ncia de factors de confusio´ (msmsEDA). I un segon
que implementa les normalitzacions, els tests i els ﬁltres (msmsTests). Tambe´ s’ha
escrit una interf´ıcie gra`ﬁca (GUI) per cadascun dels dos paquets (msmsEDA GUI i
msmsTests GUI).
En els segu¨ents apartats es discuteix el que pot faltar, o el que pot desenvolupar-
se en nous projectes per continuar la l´ınia de recerca encetada.
1.6.1 Limitacio´ en l’u´s dels SpC
La naturalesa discreta dels SpC complica la interpretacio´ de valors d’expressio´ molt
baixos, i limita la sensibilitat en la deteccio´ de secrecio´ diferencial a aquests nivells.
En la mesura en que l’expressio´ mitjana vagi guanyant entropia podrem millorar
la qualitat dels resultats. Aixo` implica que com me´s baix sigui el nivell d’expressio´
en que` estem interessats major hagi de ser el nombre de re`pliques necessari.
1.6.2 Eﬀectes batch en diagno`stic
Malgrat que els efectes batch es puguin detectar, quantiﬁcar, i corregir en expe-
riments balancejats [Scherer, 2009; Gregori et al., 2012], queda oberta la qu¨estio´
de com tractar mostres a¨ıllades en LC-MS/MS que hagin de classiﬁcar-se. En
molts cassos el biomarcador pot ser una sola prote¨ına, o un nombre forc¸a limitat
de prote¨ınes, de manera que es pugui mesurar en pacients per te`cniques immuno-
qu´ımiques on els efectes batch tenen escassa o nul.la incide`ncia. Tanmateix quan
la combinacio´ d’intensitat del senyal i mida de l’efecte sigui feble el biomarcador
pot consistir en una signatura composta per un nombre prou gran de prote¨ınes
com per aconsellar l’u´s de LC-MS/MS en diagno`stic. En aquest cas caldra` poder
calibrar la inﬂue`ncia dels factors no controlats amb mostres control.
El control ha de ser estable en el temps i contenir totes les prote¨ınes rellevants
en les concentracions degudes. Ambdues mostres, control i problema, hauran de
tractar-se i mesurar-se en paral.lel, de tal manera que tots els factors no controlats




Malgrat que la preocupacio´ principal en la majoria de me`todes desenvolupats en
proteo`mica comparativa e´s encabir la sobredispersio´ causada per la variabilitat
biolo`gica de les mostres (veure seccio´ 1.1.6), en els experiments amb mostres con-
trolades de llisat de llevat hem observat sistema`ticament un cert grau de subdis-
persio´ a tots els nivells d’expressio´ (Figura 1.1). En diferents experiments amb
secretomes de l´ınies cel.lulars hem observat un fenomen semblant.
Figura 1.1: Dispersio´ residual en experiments amb mostres controlades de llevat
amb prote¨ınes humanes afegides. Els punts sota la diagonal mostren subdispersio´.
Els models que incorporin la subdispersio´ es podran beneﬁciar d’una sensibilitat
major que el GLM basat en la distribucio´ de Poisson. El model basat en la binomial
negativa (veure equacio´ 1.4) i el model basat en l’extensio´ de la quasiversemblanc¸a
(veure equacio´ 1.5) poden explicar tant la subdispersio´ com la sobredispersio´. La
quasiversemblanc¸a modela subdispersio´ per valors positius de ψ inferiors a 1, la
binomial negativa modela subdispersio´ per valors negatius de φ majors que −1/μ
[Agresti, 2002].
L’estimacio´ de la dispersio´ introdueix un segon para`metre en el model, fent
necessa`ries un major nombre de re`pliques, que constitueix la major limitacio´ en
un laboratori de proteo`mica. La solucio´ que proporciona edgeR [Robinson et al.,
2010], similar a la implementada en limma [Smyth, 2005] per microarrays, permet
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compartir informacio´ entre prote¨ınes de nivells semblants d’expressio´ i fa menys
cr´ıtica la granda`ria de la mostra. Un treball interessant podria ser el desenvolupa-
ment d’una aproximacio´ bayessiana emp´ırica semblant per la quasiversemblanc¸a.
1.6.4 Usos possibles en altres o`miques
La tesi s’ha desenvolupat sobre conjunts de dades que so´n matrius esparses de
comptatges, semblants a les emprades en almenys altres dues o`miques : taules
RNA-seq en transcripto`mica [Wang et al., 2009] i taules d’OTUs en metageno`mica
[Wooley et al., 2010], ambdues basades en te`cniques NGS pero` responent a pre-
guntes molt diferents. Aix´ı l’estudi de la secrecio´ diferencial de prote¨ınes per l´ınies
cel.lulars de ca`ncer representa reptes estad´ıstics semblants a l’estudi de l’expressio´
gene`tica diferencial per RNA-seq, o a l’estudi de l’abunda`ncia diferencial de micro-
organismes en microbiomes per sequ¨enciacio´ del 16S ribosomal. De fet el paquet
edgeR [Robinson et al., 2010] emprat en el nostre software va estar espec´ıﬁcament
desenvolupat per ana`lisi de dades de RNA-seq.
En totes aquestes o`miques la reproductibilitat dels resultats e´s un tema clau,
i la correccio´ d’efectes batch i l’u´s dels ﬁltres post-test descrits aqu´ı podrien con-
tribuir a millorar els resultats en totes elles.
1.6.5 Possibles l´ınies de recerca derivades
Amb el model de l’equacio´ 1.7 la proteo`mica comparativa sobre secretomes basada
en SpC pot considerar-se lliure de biaix sempre que els lots de mostres estiguin
balancejats en les condicions a comparar. Aixo` imposa una restriccio´ semblant
a la observada en proteo`mica amb marcadors. Una possible solucio´ a aquesta
mancanc¸a pot consistir en l’u´s de mostres de control universals, de manera que
qualsevol condicio´ pugui mesurar-se respecte a aquest control. Aixo` podria perme-
tre comparacions no esbiaixades entre mostres en lots diferents sempre que tinguin
el mateix control. Encara que conceptualment simple, aquesta posibilitat reque-
reix un estudi acurat, i no esta` clar si caldrien mostres control diferents per cada
l´ınia cel.lular. Els efectes batch es podrien corregir per aquelles prote¨ınes en comu´
entre les condicions a comparar i els controls, i sempre que el nivell d’expressio´
sigui d’un ordre semblant. Aquest estudi implica una experimentacio´ extensiva
i pot constituir la base per a un nou projecte, juntament amb les consideracions
fetes me´s amunt en diagno`stic (veure 1.6.2).
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Un altre tema importat e´s la validacio´ de signatures moleculars en proteo`mica.
Quan el descobriment de biomarcadors porta a una simple mole`cula, o un nombre
molt limitat de mole`cules, la validacio´ es portara` a terme amb me`todes diferents al
LC-MS/MS, com ara l’ELISA per exemple. En canvi quan el BD porta a una com-
plexa mescla de prote¨ınes, a una signatura molecular, el proce´s de descobriment
i el de validacio´ esdevenen part del mateix problema. En aquest cas cal evitar el
sobreajust del discriminador al conjunt de dades emprat en el seu descobriment i
construccio´. Una l´ınia interessant d’estudi seria la implementacio´ en proteo`mica
de la metodologia general proposada per [Parry et al., 2010] en microarrays a la
llum de l’estudi MAQC-II [Shi et al., 2010].
Finalment una l´ınia de recerca paral.lela prodria ser estudiar la incide`ncia dels
efectes batch, i els llindars en el ﬁltre post-test necessaris per a millorar la qualitat




En aquesta tesi s’han explorat aspectes fonamentals en el descobriment de biomar-
cadors en proteo`mica per la te`cnica shotgun amb pe`ptits sense marcar, i mesurats
per LC-MS/MS en nombre d’espectres, estudiant secretomes de l´ınies cel.lulars de
ca`ncer. En concret s’ha demostrat:
1. Que la normalitzacio´ entre re`pliques te`cniques pel nombre total d’espectres
de la mostra proporciona resultats me´s estables que l’u´s d’esta`ndards interns.
Fins i tot quan s’empren mu´ltiples esta`ndards.
2. Que els efectes batch estan probablement presents en tots els projectes de
proteo`mica desenvolupats durant me´s d’un dia d’adquisicio´ de dades.
3. La importa`ncia de l’ana`lisi explorato`ria de dades com a eina per determinar
la qualitat d’un conjunt de dades, i per identiﬁcar la prese`ncia d’efectes
batch, de factors de confusio´ o de valors extrems.
4. Que un disseny experimental completament desbalancejat molt probable-
ment pot comportar biaixos, i aquests seran impossibles de corregir.
5. Que els efectes batch es poden i s’han de corregir en dissenys balancejats.
6. Que l’u´s d’un ﬁltre post-test que tingui en compte la intensitat del senyal i
la mida de l’efecte, me´s enlla` del nivell de signiﬁcacio´ estad´ıstica, millora la
reproductibilitat dels resultats de BD.
7. Que les llistes llargues de DEPs es veuran favorablement escurc¸ades a l’aug-
mentar els llindars del ﬁltre post-test, en comptes de reco´rrer a nivells me´s
astringents de signiﬁcacio´.
8. Que les l´ınies cel.lulars de ca`ncer mostren taxes de secrecio´ diferents en el
seu estat basal, o sota pertobacions biolo`giques.
9. Que sota un model GLM, l’equacio´ 1.7 permet una comparacio´ cel.lula-a-cel-
lula, de secretoma en l´ınies cel.lulars, lliure de biaix.
10. Que la taxa de secrecio´ i la de proliferacio´ semblen estar inversament corre-
lacionades en l´ınies cel.lulars de ca`ncer.
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11. Finalment, les solucions desenvolupades i el model dissenyat han estat im-
plementats en dos paquets R/Bioconductor, msmsEDA i msmsTests, i la seva
disseminaci i u´s per part de no experts ha estat facilitada amb dues interfcies
gra`ﬁques msmsEDA GUI i msmsTests GUI lliurement disponibles.
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1.8 Altres publicacions
Tot seguit es do´na la llista de publicacions de l’autor de treballs en bioestad´ıstica/bio-
informa`tica aliens a la tesi pero` desenvolupats durant el periode de la tesi, i que
han contribuit a la formacio´ del doctorand.
1. Inference with viral quasispecies diversity indices: Clonal and NGS approac-
hes.
Gregori J, Salicru´ M, Domingo E, Sa´nchez A, Esteban JI, Rodr´ıguez-Fr´ıas
F, Quer J
Bioinformatics. 2014 doi: 10.1093/bioinformatics/btt768
2. Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV
minor variants.
Gregori J, Esteban JI, Cubero M, Garc´ıa-Cehic D, Perales C, Casillas R,
Alvarez-Tejado M, Rodr´ıguez-Fr´ıas F, Guardia J, Domingo E, Quer J
PLoS One. 2013 Dec 31;8(12):e83361.
doi: 10.1371/journal.pone.0083361
3. A comparative study of ultra-deep pyrosequencing and cloning to quantita-
tively analyze the viral quasispecies using hepatitis B virus infection as a
model.
Ramı´rez C, Gregori J, Buti M, Tabernero D, Camo´s S, Casillas R, Quer J,
Esteban R, Homs M, Rodr´ıguez-Fr´ıas F.
Antiviral Res. 2013 May; 98(2):273-83. Epub 2013 Mar 20.
doi: 10.1016/j.antiviral.2013.03.007
4. Identiﬁcation of host and viral factors involved in a dissimilar resolution of
a hepatitis C virus infection.
Cubero M, Gregori J, Esteban JI, Garc´ıa-Cehic D, Bes M, Perales C, Do-
mingo E, Rodr´ıguez-Fr´ıas F, Sauleda S, Casillas R, Sanchez A, Ortega I,
Esteban R, Guardia J, Quer J.
Liver Int. 2013 Oct 17. [Epub ahead of print]
doi: 10.1111/liv.12362
5. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal
mutagenesis.
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Ortega-Prieto AM, Sheldon J, Grande-Pe´rez A, Tejero H, Gregori J, Quer
J, Esteban JI, Domingo E, Perales C.
PLoS One. 2013 Aug 16; 8(8):e71039. PMID: 23976977 Free PMC Article
doi: 10.1371/journal.pone.0071039
6. Molecular epidemiology and putative origin of hepatitis C virus in random
volunteers from Argentina.
del Pino N, Oubin˜a JR, Rodr´ıguez-Fr´ıas F, Esteban JI, Buti M, Otero T,
Gregori J, Garc´ıa-Cehic D, Camo´s S, Cubero M, Casillas R, Gua`rdia J,
Esteban R, Quer J.




1.9 Informe factors d’impacte
En aquest informe es descriu el factor d’impacte i el quartil on es situa la revista
en el seu camp per cada una de les publicacions que formen part d’aquesta tesi, i
en les quals he estat codirector dels projectes.
− Article 1: ”Batch eﬀects correction improves the sensitivity of signi-
ﬁcance tets in spectral counting-based comparative discovery pro-
teomics”
Revista: Journal of Proteomics
Factor d’impacte: 4.08
Quartil: Q1
− Article 2: ”An eﬀect size ﬁlter improves the reproducibility in spec-
tral couting-based comparative proteomics”
Revista: Journal of Proteomics
Factor d’impacte: 4.08
Quartil: Q1
− Article 3: ”Unconventional Secretion is a Major Contributor of Can-
cer Cell Line Secretomes”
Revista: Molecular & Cellular Proteomics
Factor d’impacte: 7.25
Quartil: Q1
Els directors de la tesi
Alexandre Sa´nchez i Pla (UB) Josep Villanueva i Cardu´s (VHIO)
33

1.10 Informe participacio´ en coautoria
En aquest informe es detalla en quines tasques va participar el doctorand en cada
una de les publicacions que formen part de la tesi i en les quals he estat codirector
dels projectes.
− Article 1: ”Batch eﬀects correction improves the sensitivity of sig-
niﬁcance tets in specttral counting-based comparative discovery
proteomics”
En aquest treball el doctorand ha participat en la concepcio´ del projecte, el
desenvolupament de la metodologia necessa`ria, l’ana`lisi i la interpretacio´ de
les dades, aix´ı com en lescriptura del manuscrit.
− Article 2: ”An eﬀect size ﬁlter improves the reproducibility in spec-
tral counting-based comparative proteomics”
En aquest treball el doctorand ha participat en la concepcio´ del projecte, el
desenvolupament de la metodologia necessa`ria, l’ana`lisi i la interpretacio´ de
les dades, aix´ı com en lescriptura del manuscrit.
− Article 3: ”A model for cell to cell comparisons”
En aquest treball el doctorand ha participat en la concepcio´ del projecte, el
desenvolupament de la metodologia necessa`ria, l’ana`lisi i la interpretacio´ de
les dades, aix´ı com en lescriptura del manuscrit.
− Article 4: ”Unconventional Secretion is a Major Contributor of Can-
cer Cell Line Secretomes”
En aquest treball el doctorand ha realitzat l’ana`lisi estad´ıstic de les dades de
proteo`mica quantitativa.
Els directors de la tesi





The ﬁrst decade of this century has seen the emergence of a number of high
throughput techniques in the ’-omics ’ ﬁelds raising each time high expectations of
success in the exploration and discovery of potential biomarkers useful in clinics
for diagnosis or prognosis. The high throughput represented also high costs per
sample, at least in their ﬁrst stage, which limited the number of samples attain-
able per study. This limited sample size together with sophisticated protocols, the
inherent biological variability, and the high number of variables simultaneously
studied, brought with them a new challenge, generically known as the curse of di-
mensionality [Bellman, 1961], or the ”many-genes-few-replicates” problem. This
problem may be described in short as follows: when the dimensionality increases,
the volume of the space increases so fast that the available data becomes sparse,
and the clusters appear more and more fuzzy; to avoid its eﬀects the sample size
should grow exponentially with the dimensionality.
The pioneer of these high throughput techniques, the gene expression microar-
rays (MA), used to interrogate the expression of a genome, had to deal in ﬁrst
term with the growing disappointment of the medical community when promising
discoveries could not be reproduced [Kuo et al., 2002; Tan et al., 2003; Ransohoﬀ,
2004; Marshall, 2004; Dupuy & Simon, 2007; Borst & Wessels, 2010; Baggerly
& Coombes, 2009; Potti et al., 2011]. A big consortium of experts led by the
FDA was formed to study the causes of this apparent lack of reproducibility in
an unprecedented community-wide eﬀort [Shi et al., 2006]. The MAQC-I study
(Figure 2.1) involved more than 600 hybridizations, across 7 platforms, including
137 participants from 51 organizations. The lessons were [Shi et al., 2006, 2008]:
1. The need for good experimental design.
2. Better suited statistical tools in discovery.
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3. Control of the false discovery rate in the multiple tests.
4. Account for non controllable confounding factors [Luo et al., 2010].
The MAQC-II study [Shi et al., 2010] was devoted to describing good practices
in the development and validation of predictors based on microarrays data, and
provided a workﬂow and a strict set of rules [Parry et al., 2010].
Figure 2.1: MAQC I
This work intends to explore speciﬁc issues in comparative pro-
teomics, and to translate and implement some of the lessons ﬁrst learned
with microarrays in the biomarker discovery stage.
2.1 Biomarkers
A biomarker [Rifai et al., 2006; Madu & Lu, 2010] may be deﬁned as a molecule, or
set of molecules, whose level is indicative of some biological state or condition. In
clinics a biomarker is relevant as predictive of disease state (diagnostic) or disease
evolution (prognostic). Diagnostic biomarkers are baseline measurements which
provide information about which patients are likely or unlikely to receive a given
treatment. An example of biomarker is the level of expression on the HER2 gene,
a factor which transmits growth signals to breast cancer cells. An overexpres-
sion of HER2 may be suggestive of a treatment with trastuzumab (HerceptinTM)
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which blocks the HER2 eﬀects. The prognostic biomarkers are pre-treatment mea-
surements informative about the evolution of the disease, the long-term outcome,
under no treatment or under a given treatment. The prognostic biomarkers are
risk indicators which could recommend more aggressive treatments. An example
is the MammaPrint test. Broad patient genotyping (genomic markers) together
with appropiate biomarkers are the key points in the paradigm of personalized
medicine, the practice which prescribes the best treatment with the least side-
eﬀects for everyone.
An ideal molecular biomarker (Figure 2.2) has been deﬁned [Madu & Lu, 2010]
as: i) a molecule which is shown to correlate with the interested outcome, ii) quick,
consistent, and economical in its determination, iii) quantiﬁable in an accessible
biological ﬂuid or clinical sample, and iv) that is readily interpretable by a clini-
cian. Besides, its expression should be signiﬁcantly increased (or decreased) in the
related disease condition, and no overlap should exist in the levels of biomarker
between healthy controls and untreated patients.
Figure 2.2: Ideal biomarker, taken from [Madu & Lu, 2010]
The ’omics ’ high throughput technologies aim to interrogate the full exome,
the full transcriptome, or the proteome of a sample at a time, and represent an
unprecedented way for biomarker discovery. Nevertheless they must be considered
as prospective discovery techniques, whose results should eventually be comple-
mented and validated by more accurate methods.
The initial promises of quick development in the biomarker discovery by the
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whole transcriptome analysis provided by the microarrays platforms were not im-
mediately fulﬁlled. The reasons are multiple [Simon et al., 2003; Ransohoﬀ, 2004;
Dupuy & Simon, 2007; Baggerly & Coombes, 2009; Rakha, 2013]:
− High initial costs and scarcity of samples brought to small sample studies.
Sometimes with poor experimental design.
− The biological variability within diseases has been found to be much higher
than expected [Kim, 2009].
− The end-points resulted not so black-and-white as supposed [Rakha, 2013].
− What was suddenly possible in a conventional biomedical research lab re-
quired sophisticated statistic and bioinformatic data analysis.
− A new type of dataset was created, with tens of thousands of variables ex-
plained by very few samples.
− A new discipline emerged with it, and countless methods of data analysis
were published at a pace diﬃcult to follow, and still new methods are being
developed [Sa´nchez-Pena et al., 2013].
As the initial costs reduced to aﬀordable levels, the availability of clinical sam-
ples has been the major drawback in biomarker discovery by microarrays. The
recent development of protocols, reagents, and microarrays able to cope with
archived formalin-ﬁxed paraﬃn-embedded (FFPE) samples [Hoshida et al., 2008]
could revolutionize the ﬁeld again. Examples are the cDNA-mediated anneal-
ing, selection, extension, and ligation (DASL) technology [Bibikova et al., 2004]
adopted by Illumina, or the molecular inversion probe technology [Absalan & Ron-
aghi, 2007] adopted by Aﬀymetrix.
Besides these improvements, and beyond genetic expression, arrays speciﬁc to
address the ﬁnding of genetic markers, like chromosomal copy number aberrations,
loss of heterozygosity, or single nucleotide polymorphism, have been developed and
oﬀer interesting and complementary diagnostic and prognostic tools [Ho et al.,
2013].
In summary, the tool once developed to quickly uncover single and simple
markers in research revealed an unexpected complexity, and because of that and
because of new developments it is becoming by itself a tool useful in clinics [Mat-
sui, 2013].
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Biomarker discovery (BD), the central topic of this work, represents just the
very ﬁrst step in biomarker development, a long process involving the following
steps [Rifai et al., 2006].
− Discovery: Identify candidate biomarkers.
− Qualiﬁcation: Conﬁrm diﬀerential abundance in the target ﬂuid by a low
throughput and highly accurate method.
− Validation: Assess sensitivity and speciﬁcity with independent samples.
− Clinical assay development: Establish sensitivity and speciﬁcity in a big
cohort with given eligibility rules, and perform assay optimization.
When the biomarker is a signature - a set of genes or proteins, in general
- the process of discovery becomes rather complex and involves strict protocols
to avoid overﬁtting the predictor to the training data set. An independent data
set is required for the validation of the signature, or in its absence a suﬃcient
cross-validation must be performed. [Parry et al., 2010]. This was the matter of
the MAQC-II study on common practices for the development and validation of
microarrays-based predictive models [Shi et al., 2010].
As an example of this complex process on a classical molecular biomarker, the
prostate-speciﬁc antigen (PSA), discovered in 1970, was found to be elevated in
men with prostate cancer in 1980, took six years to reach FDA approval for mon-
itoring cancer recurrence, and an extra 8 years for FDA approval for screening in
conjunction with a digital rectal exam. However there are still some controversies
over PSA screening as no study has successfully shown any correlation between
such screening and a decline in mortality rate [Madu & Lu, 2010].
The protein HER2 provides another example of classical biomarker. The epi-
dermal growth factor receptor (EGFR, HER1) was discovered in 1978. The proto-
oncogene Neu (HER2, ERBB2, p185) was discovered in 1982. The HER2 ampliﬁcation
in breast cancer was discovered in 1985. The ampliﬁcation of human epidermal
growth factor 2 (HER2), expressed by the HER2/neu oncogene, was associated with
a shorter time to relapse and lower survival rate in women with breast cancer in
1987. These ﬁndings were extended to ovarian cancer in 1989. The ﬁrst test for
HER2 overexpression received FDA premarket approval in 1998. ASCO guidelines
recommend HER2 testing for all breast cancers in the same year. In 2002 the FDA
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approved inclusion of the FISH (ﬂuorescence in situ hybridation) gene ampliﬁca-
tion test for HER2 gene in HerceptinTM product labelling, included in the ASCO
guidelines [Wolﬀ et al., 2007].
The MammaPrint prognostic test is a gene signature fully developed in the
omics era and provides an example of success despite some ﬂaws in its develop-
ment [Tibshirani & Efron, 2002] and recent warnings in its use [Rakha, 2013]. It is
based on the Amsterdam 70-gene breast cancer signature discovered by microar-
rays experiments [van ’t Veer et al., 2002]. It is used to analyse early-stage breast
cancers under given eligibility criteria (stage I or II, invasive, smaller than 5cm,
ER positive or negative), and predicts the risk level (high or low) of breast tu-
mour metastasis within 10 years after diagnosis. It helps physicians to determine
whether or not each patient will beneﬁt from chemotherapy to reduce recurrence
risk. The signature was discovered in 2002, and FDA-cleared as in vitro diagnostic
multivariate index assay (IVDMIA) in 2007. It can be used both on FFPE or
fresh tissue samples. MammaPrint is the only gene expression breast cancer test
currently available in the United States that has met the FDA’s IVDMIA criteria.
2.2 Proteomics
While DNA contains full information on the functions of a cell, and mRNA works
as a messenger with pieces of information sent to the machinery of the cell, proteins
are the functional part and more accurately reﬂect the phenotype. Also because
of alternative splicings and post-translational modiﬁcation a poor correlation has
been found between the mRNA and the proteins in the cell [Gygi et al., 1999].
As the protein lays in a higher functional level than mRNA it is expected that
proteomics could bring to the discovery of molecular targets and biomarkers more
eﬀectively than transcriptomics did [Gygi et al., 1999]. Nevertheless this ﬁeld
presents a few challenges to be solved.
The immediate target would be to study the proteome of tumor cells, neverthe-
less a very large fraction of the protein lysate corresponds to structural proteins,
like cellular organelles, proteosome and proteins related to cellular core functions
and protein translation. The fraction of disease speciﬁc proteins in the whole cell
lysate is negligible.
Looking for non-invasive tests the best source would be blood plasma, the most
comprehensive human proteome containing proteins from all tissues and processes,
with disease speciﬁc secreted proteins. But blood-based biomarker discovery has
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Figure 2.3: Prostate protein biomarkers, taken from [Madu & Lu, 2010]
Figure 2.4: Pie chart representing the relative contribution of proteins within
plasma. The top 22 proteins account for over a 99% of the proteome. Taken from
[Tirumalai et al., 2003]
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encountered important limitations. The proteome in plasma shows great com-
plexity and a high dynamic range. With typical proteins like albumin accounting
for over 50% of the total of proteome, and the top 22 proteins giving the 99% of
the protein content of plasma (Figure 2.4), the relative concentration of disease-
speciﬁc biomarkers is expected to be very low except in fortuitous cases [Tirumalai
et al., 2003]. Many protein biomarkers used currently in clinics as diagnosis have
concentrations in blood ﬁve to seven orders of magnitude lower than the most
abundant proteins, with a total estimated dynamic range of eight orders of mag-
nitude [Shen et al., 2005]. The Human Proteome Organization (HUPO) in its
collaborative study to characterize human plasma initially reported 9504 proteins
identiﬁed with one or more peptides and 3020 with two or more peptides, but
reanalysis of the datasets from 18 laboratories led to just 889 proteins identiﬁed
with a conﬁdence level of at least 95% [States et al., 2006]. Since more abundant
proteins interfere with the detection of less abundant proteins, extensive fractiona-
tion is required to achieve suﬃcient depth of coverage. This extensive fractionation
may be multidimensional, meaning that the proteines or the constituent peptides
are separated through successive electrophoretic and/or chromatographic steps
by diﬀerent physico-chemical properties. At the protein level by size exclusion
chromatography (SEC), and at the peptide level by strong cation exchange chro-
matography (SCX), followed by reverse phase chromatography (RP) in-line with
the mass spectrometer. It is estimated that a single blood sample could expand to
over 50 fractions, each requiring a single LC-MS/MS experiment, severely limiting
the throughput [Shen et al., 2005]. On the other hand, in biomarker discovery, a
limited number of samples with a high number of proteins identiﬁed with low abun-
dance would lead to low reproducibility and inﬂated false positives [Rifai et al.,
2006]. One possible solution, for the use of plasma in biomarker discovery, is the
depletion of the most abundant proteins, but this itself represents a challenge as
albumin and other abundant proteins act as carriers and may easily bind proteins
of interest that would be depleted along [Tirumalai et al., 2003].
2.3 Secretomes
As biomarkers speciﬁc for a particular disease arise locally from the aﬀected tissue,
it is expected that a ﬂuid closer or in direct contact with the tissue will be enriched
in these highly informative molecules. These proximal ﬂuids are local sinks for
proteins secreted or leaked from the tissue. Of particular interest is the interstitial
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ﬂuid [Rifai et al., 2006].
Disease models such as cell lines or genetically homogeneous animals provide an
important alternative to human materials for biomarker discovery. These models
provide easy sources of samples to discover biomarker candidates for subsequent
assessment. The use of the cancer secretome has recently been proposed to in-
terrogate tissue-proximal ﬂuids and conditioned media of cell lines for biomarker
discovery [Stastna & Van Eyk, 2012]. The presence of growth factors and proteases
in these ﬂuids, indicates that secretomes might help in monitoring critical aspects
of cancer progression such as invasion and metastasis. In fact, a signiﬁcant fraction
of abnormally regulated genes in cancer encode secreted proteins [Gronborg et al.,
2006; Lawlor et al., 2009; Mathias et al., 2009]. Cancer proteins contained in the
secretome have already been linked to agiogenesis, tumor invasion and metastasis,
either through cell autonomous mechanisms or tumor-stroma interactions [Stastna
& Van Eyk, 2012].
Figure 2.5: A secretome experiment workﬂow, taken from [Stastna & Van Eyk,
2012]
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Despite the apparent simplicity of secretomes in cell lines, the analysis of se-
creted proteins faces analytical challenges that interfere with the search for true
secreted tumor markers. We have to distinguish the secreted proteins from the
intracellular proteins arising from cell death and from proteolysis induced during
the cell culture handling. The conditioned medium may also contain exosomes
and microsomal vesicles, an unconventional way of secretion of proteins from the
cell [Stastna & Van Eyk, 2012]. The basic steps in the characterization of secreted
proteins in cell conditioned medium are shown in Figure 2.5.
Contamination caused by the required use of serum for cell culture, despite the
washes, has to be carefully taken into account. Also the serum-starvation phase
may cause apoptosis and cell viability has to be ensured at a high level to avoid
contamination by intracellular proteins [Villarreal et al., 2013]. Finally, when the
diﬀerential expression of secreted proteins has to be referred to a single cell in
each condition, the total amount of secreted protein and the number of viable
cells which produced the protein need to be accurately measured, excluding any
possible source of bias.
The works in this thesis are addressed to the development of statistic
tools that could help in the discovery of tumor biomarkers in cell-line
secretomes, emphasizing its reproducibility.
2.4 Elements of LC-MS/MS
LC-MS/MS stands for ”Liquid Chromatography Tandem Mass Spectroscopy”, a
high throughput technique to analyse complex protein samples.
Proteins show a very wide fan of molecular weights and physicochemical prop-
erties, and some are just soluble under very speciﬁc conditions if any at all. In this
respect, handling proteins is much more diﬃcult than peptides, entities of lower
molecular weight and generally soluble under varying conditions. In LC-MS/MS
once the protein mix sample has been puriﬁed it is digested by enzymes (usually
trypsin) into a complex mix of peptides. The advantage of trypsin digestion is
that it cleaves the proteins very speciﬁcally on the carboxy-terminal side of argi-
nine and lysine residues. This speciﬁcity greatly helps in the later identiﬁcation of
peptide sequences in the MS/MS.
The peptide digest may be fractionated by diﬀerent chromatographic or elec-
trophoretic techniques to obtain multiple samples of peptides of similar physico-
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chemical properties, depending on the dynamic range and complexity of the pro-
teome under study. Each fraction then is passed through a nanoﬂow capillary
reverse phase chromatographic column to fed the mass spectrometer to identify
and quantify each peptide.
Thus a high throughput proteomics experiment consists in the following steps
[Steen & Mann, 2004] (Figure 2.6):
1. Isolation and puriﬁcation of the proteins sample.
2. Digestion to a complex peptide mix.
3. Separation of the peptides in liquid chromatography by physicochemical
properties.
4. Electro spray ionization of the eluted peptides.
5. Characterization of co-eluting ions by MS through their mass to charge ratio
(m/z) and ion intensity.
6. Isolation and further fragmentation of parent ions by MS/MS to obtain their
amino acid sequence.
Figure 2.6: A proteomics experiment workﬂow, taken from [Steen & Mann, 2004]
In a LC-MS/MS run, the ﬁrst mass spectrometer (MS) identiﬁes the co-eluting
ions by their m/z ratio (Figure 2.7). These parent ions are captured and frag-
mented in a second MS chamber by gas collision to obtain a typical sequence of
m/z peaks, which may be identiﬁed as amino acid sequences by database searching
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and applying sophisticated statistic procedures [Nesvizhskii et al., 2007] (Figure
2.8). The output of a LC-MS/MS run consist in thousands of MS scans and
thousands of MS/MS fragmentation spectra that after peptide and protein iden-
tiﬁcation will give rise to a list of identiﬁed proteins. Additionally, both the raw
mass spectrometric data and the protein identiﬁcation data contain information
that can be used to do relative protein quantiﬁcation of the proteins present in the
sample.
Figure 2.7: Chromatogram showing relative abundances of parent ions. Taken
from [Ahn et al., 2007]
The proteins may be quantiﬁed by two methods. By ion signal intensity of
the MS scan, that is ”the signal intensity from the electrospray ionization”, or by
spectral counts (SpC), that is ”the number of peptide MS/MS spectra assigned to
each protein”. The instrument should be optimized according to the method of
choice. Multiple sampling of the chromatographic peak by survey mass spectra at
the expense of MS/MS events is required for accurate quantiﬁcation by ion signal
intensities, but this could limit the number of proteins identiﬁed. Quantiﬁcation
by SpC depends of the number of MS/MS spectra assigned to peptides with high
conﬁdence, and is favoured by a higher number of MS/MS events at the expense
of survey mass spectra.
The equipment used throughout this work (Figure 2.9) is formed by an EASY-
nLC (Proxeon Biosystems, Thermo Fisher Scientiﬁc) on-line nanoﬂow liquid chro-
matographer with a two-linear-column system, and a linear ion trap LTQ Orbi-
trap Velos mass spectrometer (Thermo Fisher Scientiﬁc, Bremen, Germany). Ions
were generated by applying 1.9 kV to a stainless steel nano-bore emitter (Proxeon,
Thermo Fisher Scientiﬁc). The instrument was controlled by the software Xcalibur
v2.1.0 (Thermo Fisher Scientiﬁc, Bremen, Germany). The experimental protocol
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Figure 2.8: Peptide identiﬁcation by MS/MS database searching, taken from
[Nesvizhskii et al., 2007]
involved the following:
1. The LTQ Orbitrap Velos was operated in data-dependent mode.
2. A scan cycle was initiated with a full-scan MS spectrum (from m/z 300 to
1600) acquired in the Orbitrap with a resolution of 30,000.
3. The 20 most abundant ions were selected for collision-induced fragmentation
in the linear ion trap when their intensity exceeded a minimum threshold,
excluding single charged ions.
4. The maximum ion accumulation time was 500 ms in the MS and 200 ms in
the MS/MS mode.
The papers collected in the appendix describe precisely the conditions used in
each experiment.
2.5 Quantifying proteins by spectral counts
Protein quantiﬁcation by ion intensity requires of sophisticated data treatment
steps such as background signal identiﬁcation, baseline correction, feature detec-
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Figure 2.9: The LTQ Velos-Orbitrap equipment used throughout this work
50
tion and alignment, and signal normalization [Sandin et al., 2011]. SpC is more
straightforward and requires just of a normalization.
A strong correlation between SpC and ion chromatograms in protein quan-
tiﬁcation has been demonstrated [Old et al., 2005; Gao et al., 2005], with SpC
more reproducible and with higher dynamic range [Zybailov et al., 2005]. A recent
expert review [Lundgren et al., 2010] considers instrument aspects, inherent limi-
tations of SpC, common normalizations by protein length or mass, and relative or
absolute quantiﬁcation by SpC.
In the early implementation of SpC diﬀerent normalizations were proposed.
The purpose of these normalizations was to account for the protein complexity
and the fact that in equal conditions longer proteins are expected to give rise
to a higher number of peptides and thus of SpC. Parameters like the molecular
weight, the amino acid sequence length, or the number of tryptic peptides were
considered. The protein abundance index (PAI) [Rappsilber et al., 2002] divides
the number of observed SpC by the number of tryptic peptides of the protein.
The Protein Abundance Factor (PAF) [Powell et al., 2004] normalizes the SpC by
the molecular weight of the protein. The normalized spectral abundance factor
(NSAF) [Zybailov et al., 2006] normalizes the SpC of each protein dividing by the
protein length and further dividing by the sum of SpC/L for all proteins identiﬁed
in the experiment.
Biomarker discovery relays on relative quantiﬁcation of a single protein in two
biological states. Under these circumstances the normalization of SpC based on
protein complexity contributes the same to the two values being compared, and for
most statistical methods should have no eﬀect. In fact [Lundgren et al., 2010] de-
mostrated that the PLGEM method, originally based on NSAF values, performed
better with raw SpC. The methods developed in this thesis are based on
raw SpC, and do not use any transformation to account for protein
complexity as described above.
2.6 Label-free diﬀerential expression
In biomarker discovery we look for diﬀerential expression between two biological
conditions, generally disease and control. That is, unbiased relative quantiﬁcation.
To ensure this unbiased comparison, labelled procedures have been employed both
in transcriptomics and in proteomics. Labelled procedures allow the early mix of
the samples to be compared. Since they are pooled they are processed together
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and any non controlled factor aﬀects equally both conditions (Figure 2.10). The
labels allow the posterior identiﬁcation of features belonging to each condition.
Two-color microarrays are an example in transcriptomics [Shalon et al., 1996]. In
proteomics diﬀerent approaches have been used. Among the most popular [Patel
et al., 2009]: Stable isotope labelling by amino acids in cell culture (SILAC),
isotope-coded aﬃnity tags (ICAT), and isobaric tags for relative and absolute
quantiﬁcation (iTRAQ). The later is commercially available with eight isobaric
tags.
Despite the advantage of labelled approaches they have potential limitations.
Complex preparation steps, requirements for increased sample concentration and
incomplete labelling, are the main issues. Labelling usually requires fractionation
since all samples are analysed together, causing a drop in sensitivity. The key of
this approach is that all samples to be compared are processed together.
Label-free proteomic analysis provide a more ﬂexible and easy alternative. This
means that each sample is processed and analysed separately (Figure 2.10). The
counterpart is high risk of bias due to uncontrolled factors aﬀecting diﬀerently one
condition than the other [Neilson et al., 2011; Sandin et al., 2011; Zhu et al., 2010;
Patel et al., 2009]. This requires carefully planned and designed experiments, to
avoid confounding and bias as much as possible.
This thesis is devoted to label-free diﬀerential expression analysis in
cell-line secretome proteomics by LC-MS/MS, using SpC.
2.7 Counts and inference
The result of a label-free proteomics experiment is contained in an expression
matrix with SpC, where each row corresponds to a diﬀerent protein and each
column corresponds to a diﬀerent sample belonging to a given biological condition.
In this matrix we may have several technical and/or biological replicates for the
same condition. We use this dataset to ﬁnd those proteins which are diﬀerentially
expressed in statistical terms, and which may be potential biomarkers. In what
follows we give some background about the statistical methods which have been
used in biomarker discovery in this ﬁeld. The last part of this section reviews the
state of the art in SpC comparative proteomics.
In the context of this work, a sample, or a replicate, is understood as a MS
experiment. That is a run of the LC-MS/MS system, where a ﬁxed amount of
total protein is analysed and quantiﬁed in its components.
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Figure 2.10: General approaches of quantitative proteomics. (a) Shotgun isotope
labelling method. (b) Label-free quantitative proteomics. Taken from [Zhu et al.,
2010]
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Table 2.1: Contingency table
Cond1 Cond2 . . . Condc Total
SpC for target protein x11 x12 . . . x1c x1o
SpC for any other protein x21 x22 . . . x2c x2o
Total SpC in sample xo1 xo2 . . . xoc n
2.7.1 Contingency tables
The most basic approach to inference with SpC considers a single sample (LS-
MS/MS run) in each condition to be compared, with no experimental replicates,
and forms a contingency table for each identiﬁed protein [Zhang et al., 2006]. The
table may contain multiple conditions, as in table 2.1, where the notation is given.
Testing whether a given protein is diﬀerentially expressed between two biological
conditions is equivalent to testing the statistical signiﬁcance of the equality be-
tween two proportions. That is, inference on diﬀerential expression is done by the
Fisher exact test, the Pearson χ2 test or the G2 test [Agresti, 2002] with the usual
restrictions. For instance the Pearson χ2 and the G2 test require a minimum of 5
counts in each cell of the table.
The Fisher exact test applies to 2x2 tables, and assumes that the row totals
and the column totals are ﬁxed. Hence any entry in the table fully determines
the others. Under the Ho of independence, conditioning on both sets of marginal
totals yields the hypergeometric distribution.












It is called exact test because it does not depend of asymptotic properties, and
the p-values may be calculated from the exact distribution.
The Pearson’s test assesses the null hypothesis of independence, that is Ho :
πij = πio πoi, i = 1, 2, j = 1, . . . , c, where πio and πoi are the marginal probabilities
of the table. The πio and πoi are estimated by maximum likelihood as the marginals
xio/n and xoi/n. When Ho is true the expected values of xij, called expected









has asymptotically a chi-squared distribution for large samples, with c− 1 degrees
of freedom for two rows contingency tables as in 2.1.
The G2 statistic is a likelihood-ratio statistic comparing the null model against






















and by the G2 statistic becomes:
G2 = −2 logΛ = 2∑
ij
xij log(xij/μˆij) (2.4)
The G2 statistic, under the null hypothesis, has asymptotically a chi-squared
distribution with c − 1 degrees of freedom, as established by the Wilks theorem
[Wilks, 1938]. The two statistics G2 and X2 are asymptotically equivalent, al-
though the convergence to the χ2 is quicker for X2 than G2 [Agresti, 2002]. The
results of the G2 test are equivalent to a GLM Poisson regression with an intercept
(see below).
These tests do not require experimental replicates. A single run (sample) of
each condition is suﬃcient. When having experimental replicates of each condition,
the SpC may be added or pooled to form a single contingency table as before. This
is however not recommended as it inﬂates the results towards lower p-values and
may result in a number of false postives. The methods given below are better
suited to the situations with experimental replicates.
2.7.2 Transforming counts
When spectral count data for replicates of each biological condition are available we
may wish to transform the counts into normally distributed variables, so that the
classical t-test or the ANOVA could be applied for diﬀerential expression inference.
Counts may be transformed by variance stabilization methods to better resemble
a normal distribution when the mean is reasonably high [Kutner et al., 2005].
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When the variance of a random variable is proportional to its mean, as is
the case for counts, the square root transformations x′ =
√
x or x′ =
√
x +√
x+ 1 are helpful. When working with proportions pij = xij/n, then the arcsin
transformation x′ = 2 arcsin
√
x is suitable. The log transformation is indicated
when the standard deviation is proportional to the mean and it is not recommended
for counts [OHara & Kotze, 2010].
In these cases, as the variance has to be estimated from the data a minimum
of three replicates are advised. Besides, the mean expression in each condition
should be reasonably high for the approximation to be reliable.
2.7.3 Generalized Linear Models (GLM)
Most biomarkers are expressed at low concentrations, even in secretomes, so the
assumptions required for the use of tests based in normality are very limiting.
Instead we may use GLM methods which do not rely on the normal distribution.
A GLM [Agresti, 2002] is speciﬁed by three components:
1. The response as a random variable Y and its probability distribution.
2. A systematic component given by a linear combination of predictor variables.
3. A link function which relates E(Y ) with the linear predictor.
The distribution of Y should belong to the exponential family, which has a
probability mass function factorizable as:
f(yi; θi) = a(θi)b(yi)exp[yiQ(θi)] (2.5)
Examples are the Poisson distribution, and the negative-binomial when the dis-
persion parameter φ is given. The link function that transforms the mean to the
natural parameter θi is known as the canonical link. The canonical link for the
Poisson or the negative-binomial distribution is the natural logarithm, and the





where xij are the design matrix elements and βj the model parameters.
Dealing with counts brings naturally to the Poisson distribution, a distribution
with just one parameter, μ, the mean.
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This distribution explains the uncertainty in the number of SpC positively
identiﬁed as belonging to a given protein, when the expected number of SpC for
this protein at a given concentration is μ.
The Poisson distribution has the property that the variance equals the mean.
The higher the number of expected counts, the higher is its variance.
μ = E[Y ] = V ar[Y ] (2.8)
When the only source of variation comes from the sampling process, as when
running technical replicates, the Poisson distribution works very well. Nevertheless
when doing biological experiments, to the typical variation in sampling technical
replicates we have to add the biological variability expected of individuals belong-
ing to the same biological condition. In these circumstances the Poisson model will
underestimate the variance and the inference may bring to false positives in dif-
ferential expression. This phenomenon is known as overdispersion. [Agresti, 2002]
The immediate alternative is the negative-binomial (NB) distribution, which al-
lows for overdispersion. The probability mass function of a NB random variable
with mean μ and dispersion φ [Agresti, 2002; Robinson & Smyth, 2008] is given
by:
Pr(Y = k) =
Γ(k + φ−1)









where the variance is a function of both mean and dispersion.
V ar(Y ) = μ+ φμ2 (2.10)
When φ → 0 the NB reduces to the Poisson distribution. Values of φ greater than
0 bring to overdispersed distributions. Strictly speaking any value φ > −μ−1 is
permitted by the model, allowing for subdispersion as well.
An extension of the GLM, making abstraction of the true distribution, considers
the mean-variance relationship
V ar(Y ) = ψμi (2.11)
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for some constant ψ. The case ψ > 1 corresponds to overdispersion. The likelihood
equations for this model are identical to the Poisson model, and the model param-
eter estimates are the same, but ψ is not assumed to be ﬁxed at 1 and estimated
from the data. This brings to the quasi-likelihood model which ﬁts the Poisson
model and multiplies the standard error estimates of the model parameters by the
square root of ψˆ, thus adjusting inference for overdispersion. [Agresti, 2002]
Still another approach to account for overdispersion is a mixed eﬀects model
(GLMM) where the intercept of a Poisson GLM model is a random eﬀects term
distributed normally [Agresti, 2002].
2.7.4 State of the art in comparative proteomics by SpC
All the methods seen so far have been used in diﬀerential expression in proteomics.
The ﬁrst to be explored were the methods based on contingency tables and varia-
tions of the t-test, or methods speciﬁcally developed for microarrays, Serial Anal-
ysis of Gene Expression (SAGE), or Digital Gene Expression (DGE). A short
description of a few selected works is given in the following list:
− [Zybailov et al., 2006] found that the natural logarithm of NSAF normalized
counts (see above) distributed normally, and applied the t-test to a quanti-
tative proﬁling of membrane-associated proteins. The data set consisted in
three biological replicates of each of two conditions. S. cerevisae cultured
on 14N-rich or 15N-minimal media. Zero spectral count values were replaced
by an empirically determined value of 0.16 to help in the log-transformation.
The samples were pairwise analysed by LC-MS/MS to minimise bias and
technical error, and the results were validated by functional analysis with
radioisotope uptake assays for selected proteins.
− [Zhang et al., 2006] compared the Fisher exact test, the G2 test, the χ2 test,
the t-test, the Audic and Claverie test (AC), and the local-pooled-error test
(LPE). The AC test [Audic & Claverie, 1997] was developed for DGE and
calculates the conditional probability of ﬁnding x2 counts in condition 2 when
x1 counts have been observed in condition 1, and requires no replicates. LPE
is a method developed for microarrays [Jain et al., 2003] which pools proteins
with similar counts by percentile intervals and ﬁts a smooth local regression
curve to estimate the variance. The test compares the median of the two
conditions using the estimated variances, and requires few replicates because
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of the pooling method. For the t-test and the LPE tests, a normalization was
performed by dividing the protein spectral count in a particular experiment
by the average spectral count across all the proteins in that experiment. This
is done so that the global average count is the same across all LC-MS/MS
experiments. The comparison of methods concluded that for fewer than
three replicates the Fisher exact test, the G2 test and the AC test performed
similarly. The t-test was better with three or more replicates. The datasets
used to compare the results consisted in a yeast lysate spiked with 6 human
proteins at 0.25%, 1.25% and 2.5%.
− [Pavelka et al., 2008] used a power-law global error model (PLGEM), pre-
viously developed for microarrays analysis [Pavelka et al., 2004], on NSAF
normalized counts. Missing values were replaced with zeros, and data were
normalized by dividing each value by the mean value of the corresponding
column. The authors compare the statistical properties of NSAF values with
transcript abundance values from Aﬀymetrix GeneChip data, and conclude
that both follow a similar power-law. The method was tested on a dataset
consisting of four biological replicates of a yeast cell culture grown in rich
medium and harvested in logarithmic phase and in stationary phase. The
results were evaluated by functional analysis, by signiﬁcant enrichment of
Gene Ontology (GO) annotation terms or Swiss-Prot keywords among the
top ranked 100 proteins.
Since 2008 the works on methods based on GLMs dominate the ﬁeld, and
though some further work could be required these methods seem to be well estab-
lished and to oﬀer wider and more ﬂexible solutions in that they may incorporate
covariates and normalizing factors as oﬀsets. Examples are:
− [Choi et al., 2008] developed a mixed eﬀects generalized linear model (GLMM)
where the sampling is modelled through a Poisson distribution and the bio-
logical variability is introduced by a normal random eﬀects term. It used a
hierarchical Bayes factor for taking into account the small number of repli-
cates in the data, which is achieved by pooling information across proteins.
The regression parameters are assumed to have prior normal distribution.
The GLMM model incorporates two oﬀset terms as normalizing factors ac-
counting for protein complexity and total sample abundance. The method
tends to give false positives (FP) with low signal/size eﬀect and incorporates
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a ﬁlter which ﬂags those proteins likely to produce FP. The method is known
as QSpec.
− [Pham et al., 2010] contrasts the performance of the beta-binomial test
against the G-test, the t-test, the t-test with log-transformed SpC, LPE, and
QSpec. The SpC are normalized to the total sample abundance. The authors
found similar results for the beta-binomial, the t-test with log-transformed
SpC and QSpec, where the former compares favourably. Although the beta-
binomial allows for overdispersion, as the negative binomial, the former does
not belong to the exponential family and cannot be used in a GLM frame-
work nor incorporate covariates.
− [Li et al., 2010] using spiked samples of whole yeast lysate with 48 equimolar
human proteins (UPS1, Sigma-Aldrich) at six abundance levels compares the
performances of the Fisher’s exact test, the Wilcoxon rank test, the Student t
test, the Poisson-based GLM, and the quasi-Poisson (quasi likelihood) GLM.
The test used with these GLMs is the F-test in an ANOVA comparing the null
and the alternative models. According to the authors this confers robustness
to the comparisons when we have all zeroes in one condition. The GLMs
incorporate an oﬀset as normalizing condition for total sample abundance.
At the highest spike level all methods performed similarly in identifying
almost all the spiked proteins. At the two lowest spike levels the quasi-
likelihood outperformed the other tests, at the cost of an increased number
of false positives. The artiﬁcial low p-values are related either to 0 SpC in
all replicates in one condition, or to non-zero values being all equal in one
condition. Such proteins are ﬂagged as to have NA or 0 cv values, and may
be subject to separate analysis.
− [Lundgren et al., 2010] in an expert review discusses the main statistical
methods applied to proteomics data, with a mention to the LPE test, to
the work of Zhang [Zhang et al., 2006] comparing multiple tests, to PLGEM
[Pavelka et al., 2008], and QSpec [Choi et al., 2008]. The review reports the
ﬁnding that the reanalysed results of the Choi et al.’s synthetic data sets
omitting the two normalizing oﬀsets are indistinguishable of the original.
The same was observed with PLGEM using both the raw and the abundance-
normalized SpCs.
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− [Leitch et al., 2012] compare the GLM and GLMM models with special at-
tention to the GLM with quasi-likelihood or with the negative-binomial dis-
tribution, and to the GLMM provided by QSpec. The authors conclude that
the quasi-likelihood is less conservative than the QSpec is, and the negative-
binomial is more conservative. Both QSpec and quasi-Poisson are not robust
to the zero variance problem. The negative-binomial is not robust when there
are no observations in one of the groups. One last conclusion is that there
is great potential for future research in this ﬁeld. Of note, the authors used
the F-test as proposed by [Li et al., 2010] for the quasi-likelihood [Li et al.,
2010], but the Wald test for the negative-binomial GLM.
In this work we implemented the Poisson GLM, the negative-binomial
GLM, and the the quasi-likelihood GLM extension.
2.8 Lessons in biomarker discovery
The issue of reproducibility is the most crucial in BD. The almost 20 years of
experience on BD in transcriptomics is worth being considered in depth, in beneﬁt
of younger omics, particularly proteomics. In this section the main lessons learned
in BD (including experiences in proteomics) are introduced. These lessons bring
us to the objectives of this work.
2.8.1 Normalization
When comparing equal amounts of total substance between two biological con-
ditions, diﬀerences in the treatment and measurement process of two samples
introduce bias in the relative measures, and normalization attempts to correct this
eﬀect. Normalization is then understood as an attempt to compensate globally
for systematic technical diﬀerences that aﬀect equally all features in a sample. In
sample normalization, all features in the sample are submitted to the same trans-
formation. Ideally sample normalization brings the measures in all samples to the
same scale, with identical origin.
Quantiﬁcation by peak intensity requires of sophisticated data pre-processing
and normalization steps [Degroeve et al., 2011; Sandin et al., 2011; Callister et al.,
2006], the same as microarrays data [Bolstad et al., 2003; Park et al., 2003]. Nor-
malization of SpC data is much simpler. The most extended method assumes that
for a given amount of total protein, the sum of SpC should be the same. In general
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when GLM models are used [Choi et al., 2008; Li et al., 2010; Leitch et al., 2012]








= α + βx
log(μ) = log(size) + α + βx (2.12)
where μ is the expected expression of a given protein, size is the normalizing
condition, and α and β are the model parameters, with x equal to 0 for the control
condition, or equal to one for the tumor condition. The term log(size) is the
oﬀset. Diﬀerent covariates or blocking factors may be added to this simple model.
This is independent of the underlying distribution for the expression level y of this
protein.
Diﬀerential expression in the ’omics ’ ﬁeld is based on basic assumptions, not
always explicitly given. When these assumptions are roughly fulﬁlled the compar-
isons between two biological states may be considered as nearly unbiased, provided
that a good experimental design is used. These assumptions are usually taken for
granted and receive no criticism in most, if not all, studies. In transcriptomics and
proteomics, where equal amounts of substance gathered from two biological condi-
tions are measured, it is considered that the cells produce globally an almost equal
quantity of total substance. Under this assumption comparing equal amounts of
substance corresponds to comparing the substance produced by equal number of
cells. And this is a cell to cell comparison, where the cell is the biological unit
of interest. Speciﬁcally when studying the full proteome of a tissue a very large
fraction of intracellular proteins corresponds to structural proteins comprising cel-
lular organelles, protein complexes such as the proteosome, and proteins related
to cellular core functions as metabolism and protein translation. Structural and
house-keeping proteins account for the vast majority of the proteome, and the as-
sumption of almost equal yield of total protein per cell in the two biological states
may be accepted.
When studying secretomes this assumption deserves a careful con-
sideration, as the number of involved proteins is drastically reduced,
and no structural proteins or related to the metabolism, are expected.
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If it fails, the normalization given in equation 2.12 could be non appro-
priate. This crucial issue is also investigated and solved in the thesis by
means of an speciﬁc normalization based on oﬀsets.
2.8.2 Eﬀect size and p-values
In the early times of microarrays, BD relied simply on observed fold-changes.
Later the t-test or a rank test was used on transformed and normalized data to
infer signiﬁcance through a p-value assigned to each feature. The statistical meth-
ods grew in sophistication and multitest p-value adjustments with control of the
false discovery rate were introduced [Allison et al., 2006]. The result of a transcrip-
tomics study was a long list of features ordered by p-values. The top features were
the statistically most signiﬁcant. In this context and with diﬀerent microarrays
platforms commercially available, promising published biomarkers with apparently
very high sensitivity and speciﬁcity could not be reproduced in diﬀerent laborato-
ries, or on diﬀerent platforms. The next quotation exempliﬁes the situation in the
years 2004-2006.
The unresolved issue of measurement variability and measuring vari-
ability has hampered the great hopes researchers had with the advent of
microarrays technology and the human genome sequence project. Since
consensus technological, analytical, and reporting processes were (and
still are) largely missing, it appeared that not only were gene expression
data irreproducible, but also the results were very much dependent on
the choice of analytical methods. A lively discussion on the validity of
microarrays technology resulted in publications and comments like ”Mi-
croarrays and molecular research: noise discovery?” (Ioannidis 2005),
”An array of problems” (Frantz 2005), countered by ”Arrays of hope”
(Strauss 2006), and ”In praise of arrays” (Ying and Sarwal 2008), and
publications which raise questions about the reproducibility of microar-
rays data (Marshall 2004; Ein-Dor et al. 2006) or showing increased
reproducibility (Dobbin et al. 2005b; Irizarry et al. 2005; Larkin et al.
2005).
Andreas Scherer in Ch. 1 in Scherer [2009]
Under this pressure, regulatory (FDA) and academic authorities, together
with commercial institutions constituted the MicroArray Quality Control (MAQC)
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Consortium [Shi et al., 2006]. The MAQC brought together more than a hundred
researchers at 51 academic, government and commercial institutions to assess the
performance of seven microarrays platforms in proﬁling the expression of two com-
mercially available RNA sample types. Results were compared not only at diﬀerent
locations and between diﬀerent microarrays formats but also in relation to three
more traditional quantitative gene expression assays [Shi et al., 2006]. The Nature
Biotechnology issue of September 2006 was fully dedicated to the results of this
MAQC-I study. Its editorial emphasized the importance of the project.
No technology embodies the rise of ’omic’ science more than the
DNA microarray. First reduced to practice in the early 1990s, it has
since undergone numerous iterations, adaptations and reﬁnements to
achieve its present status as the platform of choice for massively paral-
lel gene expression proﬁling. Today, several thousand papers describing
data from microarrays are published each year. Sales of arrayers, ar-
ray scanners and microarray kits to the academic and industrial R&D
community represent a multi-billion-dollar business. The microarray
has even made its ﬁrst forays into the clinic, with the US Food and
Drug Administration’s approval of the ’AmpliChip’ to help physicians
tailor patient dosages of drugs that are metabolized diﬀerentially by cy-
tochrome P450 enzyme variants. And yet doubts linger about the repro-
ducibility of microarray experiments at diﬀerent sites, the comparability
of results on diﬀerent platforms and even the variability of microarray
results in the same laboratory. After 15 years of research and devel-
opment, broad consensus is still lacking concerning best practice not
only for experimental design and sample preparation, but also for data
acquisition, statistical analysis and interpretation. Though problem-
atic for bench research, lack of resolution of these issues continues to
even more seriously hamper translation of microarray technology into
the regulatory and clinical settings. Indeed, several regulatory authori-
ties have been wrestling with the problem of how and when (and indeed
whether) to implement microarray expression proﬁling data as part of
their decision-making processes.
. . .
Clearly, microarrays have a long way to go before they can be used to
support regulatory decision-making or accurate and consistent predic-
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tion of patient outcomes in the clinic. But the MAQC study has given
us a solid foundation from which to build.
Nature Biotechnolgy editorial in the September 2006 issue, 24 (9) 2006
The conclusions of the MAQC-I [Shi et al., 2006] study may be summarized
as follows [Shi et al., 2008]. With careful experimental design and appropriate
data transformation and analysis, microarrays data can be reproducible and com-
parable among diﬀerent patforms and laboratories. The fold change results from
microarray experiments correlate closely with the results from orthogonal assays
like quantitative reverse transcription PCR (qRT-PCR).
One goal of the MAQC study was to optimize intra- and inter-platform repro-
ducibility. The approach to achieve the highest degree of reproducibility was to
limit the number of transcripts identiﬁed as diﬀerentially expressed (DEG), and to
sort the corresponding genes using fold-change ranking with a nonstringent p-value
cutoﬀ.
These results were later questioned [Chen et al., 2007] and then reinforced
comparing diﬀerent gene selection procedures, and with the help of additional
simulations [Shi et al., 2008]: ”We recommend the use of FC-ranking plus a non-
stringent P cutoﬀ as a straightforward and baseline practice in order to generate
more reproducible DEG lists. Speciﬁcally, the P-value cutoﬀ should not be stringent
(too small) and FC should be as large as possible” and ”Using FC and P together
balances reproducibility, speciﬁcity, and sensitivity. Control of speciﬁcity and sen-
sitivity can be accomplished with a P criterion, while reproducibility is enhanced
with an FC criterion.”
The top genes are not required to be the most statistically signiﬁcant but those
with the highest eﬀect size with a reasonable multi-test adjusted p-value.
This lesson is implemented in this work in the form of a post-test
ﬁlter ﬂagging as unlikely reproducible those proteins with low signal
and/or low fold-change despite being statistically signiﬁcant. The list
of diﬀerentially expressed proteins is ordered with increasing adjusted
p-values, with the corresponding ﬂag.
2.8.3 Batch eﬀects
The conclusions of the MAQC-I study are directly linked to the problem of many-
genes-few-replicates. This suggests that by extending the number of replicates
reproducibility may be improved, besides increasing the power in the detection
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of DEGs. Unfortunately it has been observed that by increasing the number of
replicates the chances of bias increase as well (Speed T. in [Scherer, 2009]).
When the experiments are collected within a long period of time bias may
be unavoidable. This is related to the so known batch eﬀects. Although good
experimental design with appropriate use of randomization and blocking at each
step may greatly help, batch eﬀects seem to be unavoidable and ubiquitous.
The batch eﬀect is deﬁned to be systematic an unintentional, in contrast with
the experimental noise which is random in nature. It refers exclusively to system-
atic technical diﬀerences when samples are processed and measured in diﬀerent
batches or in diﬀerent times. These eﬀects may be visualized by multidimen-
sional techniques like Principal Components Analysis (PCA) (Figure 2.11), Singu-
lar Value Decomposition (SVD), Hierarchical Clustering (HC), or Heatmaps (HM)
[Scherer, 2009; Luo et al., 2010; Chen et al., 2011; Lazar et al., 2013]. Ideally the
samples should cluster by treatment level, with independence of the time in which
they were treated and measured (See Figure 2.11).
Figure 2.11: Visualization of the bias caused by batch eﬀects, by PCA. Taken
from [Luo et al., 2010]. (a) MD Anderson breast cancer data set. Training/test
split was performed according to hybridization dates, the ﬁrst 130 samples assayed
were used as training set and the remaining 100 samples were used as test set. (b)
Hamner lung carcinogen data set. Two batches in training set hybridized in 2005
and 2006, and two batches in test set hybridized in 2007 and 2008.
Because of the its systematic nature, the worst manifestation of batch eﬀects is
bias. And this usually occurs when most disease (or control) samples are processed
separately of the others. As an example of the consequences of bias, in 2002 a study
reported that a blood test, based on MS signatures, was 100% sensitive and speciﬁc
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to detect ovarian cancer [Petricoin et al., 2002; Conrads et al., 2004]. A commercial
screening test had to be introduced by 2004, but was delayed amid concerns of
reproducibility. It was demonstrated that the study was seriously biased [Baggerly
et al., 2004, 2005; Ransohoﬀ, 2005b] with bias caused by batch eﬀects. Another
example on a test for ovarian cancer based on a microarrays signature is given by
[Dressman et al., 2007] and [Baggerly et al., 2008]. Batch eﬀects, together with
overﬁtting in training predictors, are the major causes of ﬂawed biomarkers and
signatures [Baggerly & Coombes, 2009].
A mild manifestation of batch eﬀects occurs when the batches are balanced in
the number of samples of each biological condition to be compared. This manifes-
tation is an increase of the intra-class variance reducing the power of the statistical
tests for diﬀerential expression. Diﬀerent methods of correction of batch eﬀects
have been proposed and compared [Luo et al., 2010; Chen et al., 2011; Lazar et al.,
2013].
Batch eﬀects are widespread and aﬀect all omics [Ransohoﬀ, 2005a; Scherer,
2009; Leek et al., 2010; Auer & Doerge, 2010; Schloss et al., 2011; Valsesia et al.,
2013]. In words of one of the fathers of microarrays analysis:
Samples might come in one at a time, over months or years, but
are commonly collected in batches. However the collection, processing
and analysis are conducted, time or batch eﬀects are unavoidable. Im-
portant though design is, and it is rightly emphasized in the book, there
is in general little chance of entirely eliminating these eﬀects. We must
do our best with good design, but we must also plan to be in a position
to identify and subsequently correct for those eﬀects we are unable to
eliminate by design.
Terry Speed in the foreword to the book [Scherer, 2009]
In the R package msmsEDA we implemented multidimensional tools
to evidence putative outliers and batch eﬀects, and in the R package
msmsTests we implemented GLM tools able to cope with block factors





The establishment of a new proteomics biomarker discovery lab in the Vall d’Hebron
Oncology Institute has oﬀered the opportunity to develop tools and methods in
comparative proteomics data analysis, and to contribute to translate some of the
experience acquired in the omics data treatment with microarrays of over a decade
to the ﬁeld of BD with proteomics. In this respect, the objectives in the thesis
were the implementation of tools and methods speciﬁcally devised to for:
− Data analysis of label-free shotgun proteomics experiments based on spectral
counts.
− Dataset quality evaluation in terms of outliers and confounding factors.
− Modelization and normalization of cell-line secretomes data.
− Filters which could help to reinforce the reproducibility of biomarker discov-
ery results in this ﬁeld.
− Production of R packages encapsulating the tools developed.






All publications presented in this thesis have been submitted to international peer-
reviewed journals. In what follows a summary and a description of the main
ﬁndings in each paper is given. More than a reiteration of the contents of these
papers, the ﬁndings and the conclusions relevant to the thesis are highlighted. It
is an exercise of rewriting what this author considers as more relevant once the
paper has been published.
The publications are divided in methodological, software, and applications.
In the methodological papers the main contributions fulﬁll the objectives of the
thesis. In the application papers, the methodology developed is applied to uncover
biological responses in cell-line biomarker discovery. Under software, the packages
developed along the works and contributed to Bioconductor are presented.
The chapter starts with a list of the publications with impact scores, and a
summary of the software produced, then there is a section devoted to each paper
and package. At the end of the chapter there is a section with a summary of
other publications, in the same period 2011-2014. These publications, although
not related to the contents of the thesis, belong to the ﬁeld of bioinformatics /
biostatistics, speciﬁcally to the NGS domain, and contributed to this doctorand
education during the PhD.
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Software
R/Bioconductor packages
All software was developed in the R statistical environment and language [R Core
Team, 2012], and the following two packages were produced:
1. msmsEDA package
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Functions for the exploratory data analysis (EDA) of LC-MS/MS SpC datasets.
Visual tools to discover outliers and eventual confounding factors. Dispersion
analysis by factor, to help in choosing the best model.
2. msmsTests package
Statistical tests for label-free LC-MS/MS data by spectral counts, to discover
diﬀerentially expressed proteins between two biological conditions. Three
tests are available: Poisson GLM regression, quasi-likelihood GLM regres-
sion, and the negative binomial of the edgeR package. The three models
admit blocking factors to control for nuisance variables. To assure a good
level of reproducibility a post-test ﬁlter is available, where the user may set
the minimum eﬀect size considered biologicaly relevant, and the minimum
expression of the most abundant condition.
Graphical user interfaces
Two graphical user interfaces (GUI) have been developed based on the functions
in the two R packages, and with the help of the infrastructure provided by the R
packages gWidgets and RGtk2 [Verzani, 2012; Lawrence & Verzani, 2012; Lawrence
& Temple Lang, 2010].
1. msmsEDA GUI
Useful in the exploratory data analysis of a LC-MS/MS experiment to assess
the data quality, identify putative outliers, and detect potential batch eﬀects
in the dataset.
2. msmsTests GUI
Useful in BD by SpC, where a number of parameters may be easily adjusted




4.1 Paper 1: Batch eﬀects
J Proteomics. 2012 Jul 16;75(13):3938-51. doi: 10.1016/j.jprot.2012.05.005.
Epub 2012 May 12.
4.1.1 Aim
The aim of this work was to study the inﬂuence of bacth eﬀects in label-free
comparative proteomics based on SpC. It is done on one side by detecting them
using multidimensional methods as in transcriptomics [Scherer, 2009]. On the
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other, when observed, by assessing the improvement in the BD results obtained
by common batch correction methods [Luo et al., 2010; Chen et al., 2011; Lazar
et al., 2013].
4.1.2 Background
See section 2.8.3 with a description of the importance of batch eﬀects in the ’-
omics ’.
4.1.3 Findings
A number of technical replicates of yeast lysate with and without spiked human
proteins were measured at diﬀerent dates spanning a few months. Also, to ap-
proach real life BD proteomics projects, control/treatment experiments with can-
cer cell lines secretomes spanning a few months were performed, and the datasets
were studied by EDA techniques.
1. The experiments done with technical replicates of yeast lysate, using each
time the same quantity of total protein, showed that the most reliable and
stable sample normalization was to scale the dataset to the total signal ob-
tained for the sample. This option showed far better results than using
internal controls, even when multiple controls were employed.
2. When technical replicates of a yeast digest were run by LC-MS/MS for a
few days, diﬀerences in the abundance of proteins could be observed among
the runs, even after normalization by total SpC. The analysis of the data
by HC and PCA revealed a clear sample partitioning by the day of the
LC-MS/MS run (Figure 4.1). The inﬂuence of the observed batch eﬀects
was assessed by a GLM Poisson test between yeast samples run on diﬀerent
days, which gave several signiﬁcant diﬀerences attributable to non controlled
variables inﬂuencing the experiment (Figure 4.2). Conversely, no signiﬁcant
diﬀerences were found when comparing samples run in the same day.
To further conﬁrm this ﬁnding, a number of samples composed of 48 equimo-
lar human proteins (Universal Proteomics Standard Set, UPS1, Sigma-Aldrich R©)
were run on consecutive days. The results with the UPS1 samples conﬁrmed
the trend previously observed with the yeast samples. Furthermore, this
data conﬁrms our view of a sample batch as being the samples run by LC-
MS/MS during the period of 24 h, since this is the smallest fraction of time
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Figure 4.1: Batch eﬀects on yeast lysate. PCA of yeast lysate samples measured
in LC-MS/MS runs performed on diﬀerent dates. Each run is colored diﬀerently.
upon sample comparison showed non-signiﬁcant variability. This data shows
that sample batch eﬀects seem to be involved in the day-to-day variability
observed in spectral counting-based quantitation.
3. Our limited experimental dataset show that long hydrophobic peptides elut-
ing at the end of reversed-phase chromatography tend to be more sensitive
to batch eﬀects.
4. To study the inﬂuence of the batch eﬀects and the correction methods, a set
of technical replicates of 500ng standard yeast lisate samples spiked with 200
and 600fm of UPS1 were analysed spanning a few weeks, in ﬁve balanced
runs according to the experimental design in table 4.1.
Table 4.1: Experimental design.
Batch
Spiking 12.01 13.01 20.01 03.02 06.02
500ng yeast + 200fm UPS1 2 2 2 3 3
500ng yeast + 600fm UPS1 2 2 2 3 3
The eﬀect of two methods of batch eﬀects correction on the performance
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Figure 4.2: Volcano plot showing false positives due to batch eﬀects on yeast lysate.
of two typical statistical tests was evaluated. The statistical tests selected
were the square root transformation of SpC followed by ANOVA [Kutner
et al., 2005], and the quasi-likelihood with log link (QLLL) test [Li et al.,
2010; Agresti, 2002]. The two methods of batch correction selected, were the
batch mean-centering [Luo et al., 2010; Lazar et al., 2013], and a blocking
factor in the model [Kutner et al., 2005; Agresti, 2002]. The batch mean-
centering is an additive correction that brings the center of all batches on the
same point [Luo et al., 2010]. On the other hand a blocking factor contributes
an additive correction (a shift) for ANOVA, or a multiplicative correction (a
scaling) for the QLLL.
Table 4 shows the results of the tests at two typical signiﬁcance levels, 0.05
and 0.01, when carried out on the raw SpC matrix, after the correction by
batch mean centering, and with a batch block factor in the model.
Both the ANOVA and the QLLL test clearly beneﬁt from the batch eﬀect
correction in terms of TP. The impact in the number of the FP may be
reduced with a more stringent signiﬁcance level. The QLLL is not robust to
very low variances [Leitch et al., 2012] and produces a higher number of FP.
The reduced variance is a direct consequence of the batch eﬀects correction.
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Table 4.2: Incidence of batch eﬀects correction.
Signiﬁcance Signiﬁcance
0.05 0.01
Test Data treatment TP FP TP FP
Raw SpC 22 0 18 0
ANOVA Block factor 44 4 29 1
Batch mean centering 45 10 31 4
Raw SpC 22 2 19 0
QLLL Block factor 47 56 45 21
Batch mean centering 42 31 28 5
According to the area under the curve (AUC) in the ROC curves, modelling
with a blocking factor gives better results than the mean-centering approach
with both tests (Figure 4.3). The FP were fully controlled in both tests by
excluding the signiﬁcant features with low signal (<2 mean Spc in the most
abundant condition) or low eﬀect size (absolute logFC <1).
Figure 4.3: ROC curve showing the impact of the batch eﬀects correction. Left)
Quasi-likelihood. Right) ANOVA on square root transformed SpC.
5. Besides the spikings, two biological studies on cancer cell lines were evaluated
for batch eﬀects by EDA. The two studies represent two diﬀerent levels of
biological signal. The ﬁrst with a moderate eﬀect (HMEC treatment with
TGF β), and the second with a strong eﬀect (MCF7 versus MDA231). These
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evaluations show that batch eﬀects are probably present on every proteomics
project done for more than one day of instrument data acquisition. It also
shows that they can be corrected when using a proper experimental design
followed by a batch eﬀects correction method. Despite not having evaluated
the signiﬁcance tests for these projects because the list of true positives
is unknown, the data showed that only after batch eﬀect correction could
the two conditions in the HMEC with TGFβ project be separated (Figure
4.4). In the other project (MCF7 versus MDA231), where the diﬀerences in
abundance for several proteins in the secretomes are large, batch eﬀects were
not able to mask the biological signal between the two conditions, but sample
batches were still evident by EDA tools.
Figure 4.4: Average linkage HC dendrogram showing batch eﬀects in a project on
HMEC cells treated with TGFβ.
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4.1.4 Conclusions
1. Normalizing by total SpC by sample results in a more stable normalization
than using internal standards, even when multiple standards are used.
2. Batch eﬀects are probably present on every proteomics project done for more
than one day of instrument data acquisition.
3. Fully unbalanced LC-MS/MS runs will likely produce biased results. The
eventual bias cannot be corrected by any means.
4. When the LC-MS/MS runs are balanced in the conditions to compare, the
batch eﬀects produce a higher intraclass variability, but the results are un-
biased.
5. The intraclass variance may be reduced by batch eﬀects correction methods.
6. The reduced variance after batch eﬀects correction may produce a high num-
ber of FP, which may be controlled by a signal and eﬀect size ﬁlter.




4.2 Paper 2: Reproducibility
J Proteomics. 2013 Dec 16; 95:55-65. doi: 10.1016/j.jprot.2013.05.030.
Epub 2013 Jun 11.
4.2.1 Aim
As mentioned in the introduction (see section 2.8.2) the issue of reproducibility is
very important in BD. As pointed out by the MAQC-I study [Shi et al., 2006, 2008]
low p-values are no guarantee of reproducibility. Instead, features with a combi-
nation of good eﬀect size and low p-value are seen as reliably reproducible. The
aim of this work was to study feature ﬁlters with a good balance of reproducibility
and sensitivity in our ﬁeld.
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4.2.2 Background
Feature ﬁltering is a method commonly used in microarray data analysis [Pounds
& Cheng, 2005] to reduce the impact of multiple test p-values adjustment with
FDR control. This is because of the huge multiple testing penalty incurred when
dealing with tens of thousands of variables.
A priori ﬁlters - that is ﬁlters used before the tests - should be non-speciﬁc
or unsupervised so that the sample class labels are not seen before the test, as
data-based ﬁltering constitutes by itself a statistical test [Bourgon et al., 2010].
Examples of the most used ﬁlters are by signal or by variance. Nevertheless when
using these ﬁlters together with a FDR correction method, a FDR bias may occur
despite the ﬁlter/test independence. The reason is that FDR methods rely on
the assumption that the null p-values follow a uniform distribution. To keep the
distribution uniform, the probability to exclude a feature should be independent
of the test p-value [Iterson et al., 2010]. Because of all these reasons the use of a
priori ﬁlters is an active ﬁeld that deserves further study [Iterson et al., 2010]. In
transcriptomics, where tens of thousands of probes are evaluated, the impact of
ﬁltering by signal or variance up to a 40-50% seems not very relevant. Instead in
cell-line secretomes, where the number of features studied is in the order of very
few thousands, this impact might not be negligible.
According to clues observed in the previous work, and to the recommendations
of the MAQC-I study [Shi et al., 2006, 2008], an alternative could be to use a
posteriori or post-test ﬁlters together with a less stringent p-value threshold. The
increase in FP due to a less stringent p-value could be largely compensated by the
ﬁlter. The aim is to limit the FPs beyond the nominal FDR value and to increase
the reproducibility of declared DEPs.
4.2.3 Findings
1. To study the impact of the proposed ﬁlters a series of experiments with
spikings were done. The experimental setting consisted in a yeast tryptic
digest with diﬀerent controlled amounts of 48 equimolar human proteins
(Universal Proteomics Standard Set, UPS1, Sigma-Aldrich R©). Each sample
consisted in 500 ng of yeast lysate with either 100, 150, 200, 400, 600 or 750
fm of UPS1. Despite being equimolar, the 48 human proteins span the full
range of observed SpC because of its diﬀerent structural complexities and
physico-chemical properties (see Figure 4.5), providing a good model for this
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study.
Figure 4.5: UPS1 expression range. The UPS1 proteins in red, and the yeast
proteins in black, on the SpC cumulated distribution curve.
Five diﬀerent statistic tests were used. GLM Poisson [Agresti, 2002], GLM
quasi-likelihood [Li et al., 2010], edgeR [Robinson et al., 2010], QSpec [Choi
et al., 2008], and the t-test on square root transformed SpC [Kutner et al.,
2005]. The tests compared pairs of the given conditions. The confusion
matrices (truth tables) of the tests with and without post-test ﬁlter were
built out of the results and compared. The confusion matrix without ﬁlter
was constructed with the signiﬁcant proteins at an adjusted p-value threshold
of 0.01, to limit the number of FP. The confusion matrix with ﬁlter was
constructed with the signiﬁcant proteins at an adjusted p-value threshold of
0.05, thus relaxing the former threshold, and showing a minimum of 2 mean
SpC in the most abundant condition, and a minimum absolute logFC of 0.8
(See table 4.3).
The ﬁrst observation was that the positive predictive value (PPV), measured
as the ratio TP/(TP+FP), improved notably with the ﬁlter, and that the
diﬀerences among tests were reduced. The sensitivity also increased with the
ﬁlter, while the FDR decreased as a general trend.
No test dominates absolutely over the others when considering all compar-
isons made, although the Poisson, the quasi-likelihood and edgeR work rea-
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Table 4.3: Results with and without post-test ﬁlter
Comparison Statistical Adjusted Filter + adj. TP among 35
test p.val ≤ 0.01 p.val ≤ 0.05 top ranked
TP/FP TP/FP
750 vs 150 Poisson 18/2 26/1 28
4 repl. 4 QL 7/1 21/1 21
edgeR 16/1 19/0 28
t-Test 8/6 15/1 20
QSpec 25/16 (24/1) 24/1 24
600 vs 150 Poisson 14/8 20/9 20
6 repl. 4 QL 14/12 23/4 18
edgeR 14/5 18/8 21
t-Test 13/3 17/3 19
QSpec 20/35 (17/9) 17/6 16
600 vs 200 Poisson 27/9 26/0 26
6 repl. 12 QL 28/7 29/2 28
edgeR 23/4 26/0 28
t-Test 21/2 22/0 29
QSpec 29/30 (25/1) 25/0 22
400 vs 200 Poisson 11/6 12/1 19
4 repl. 12 QL 3/0 8/0 22
edgeR 6/0 11/0 21
t-Test 0/0 4/0 16
QSpec 15/18 (6/0) 6/0 15
200 vs 100 Poisson 1/4 1/3 9
12 repl. 4 QL 0/2 0/0 8
edgeR 0/3 1/2 11
t-Test 0/0 1/0 14
QSpec 5/20 (1/2) 1/2 7
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Figure 4.6: Results with and without post-test ﬁlter. Bar diagram with the data
in table 4.3. TP.01: TP p.val ≤ 0.01, FP.01: FP p.val ≤ 0.01, TP.f05 TP
p.val ≤ 0.05 and post-test ﬁlter, FP.f05: FP p.val ≤ 0.05 and post-test ﬁlter.
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sonably well in all circumstances. Remarkably the post-test ﬁlter minimizes
the diﬀerences among tests, some of them highly sensitive to problems caused
by low signal and/or extremely low variances [Leitch et al., 2012; Lundgren
et al., 2010; Choi et al., 2008].
2. Besides the experimental setting, an extensive in-silico simulation was carried
out (see Figure 4.7). The Poisson distribution parameter, λ, of the set of
proteins in six replicates of samples of 500 ng of yeast lysate with 600 fm
of UPS1 was estimated. For increasing fractions of DEPs, ranging from 1%
to 25%, 1000 datasets of 4+4 samples were generated with indices of DEPs
randomly generated. The FC for the DEPs were generated from a uniform
distribution between 2 and 5, and its signs were obtained from a Bernouilli
with probability 0.5. For each fraction of DEPs, the 1000 datasets provided
a set of confusion tables from which the empirical distributions of power
and FDR were obtained. For both, the test at an adjusted p-value of 0.01,
and for the post-test ﬁlter with an adjusted p-value relaxed to 0.05. The
proteins ﬁltered out were the signiﬁcant with less than 2 average SpC in the
most abundant condition or with absolute LogFC below 0.8. The tests used
were the GLM Poisson, the quasi-likelihood extension of the GLM, and the
negative-binomial provided by the R package edgeR.
At a fraction of 1 or 2% DEP both distributions span over the full range of 0
to 1, and this is consistent with the diﬃculty of discovering DEP at very low
SpC. As the fraction of DEP increases the importance of those expressed
at a low level is limited, because of the uniform distribution of DEP over
the estimated lambdas. It was observed how after the post-test ﬁlter the
sensitivities increased, and that this eﬀect was stronger as the fraction of
DEP increased too. It was also observed how the FDR values were pushed
up too, although seemingly at a lower extent. In summary, in this simulation,
ﬁltering and using a higher p-value threshold brought to an increase in the
number of both TPs and FP, but with a better TP/FP ratio.
To prove the inﬂuence of the poor reproducibility of DEP expressed at very
low level in the number of FP still observed, the simulations were repeated
restricting the DEP to those showing a λ above 1 SpC. The variability pre-
viously observed on FDR and power was now very much restricted. Indeed,
the distribution of the FDR values was now compressed at values near 0,
with no visible diﬀerences between the full set and the ﬁltered one. The
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distribution of sensitivity values showed the same trend as before, although
slightly magniﬁed, with higher power for the ﬁltered dataset (see Figure 4.7).
Figure 4.7: Empirical distribution of power and FDR by simulation, when the
simulated DEPs are restricted to have a λ ≥ 1. Inference with edgeR.
This diﬀerence could only be caused by the proteins with λ < 1, conﬁrming
that a low signal leads easily to lack of reproducibility.
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4.2.4 Conclusions
1. The results obtained in this work prove that a post-test ﬁlter with reasonable
eﬀect size and signal level thresholds helps to increase the reproducibility of
comparative proteomic analysis.
2. The signal and eﬀect size post-test ﬁlter improves the results of the most
common methods for SpC data analysis, and reduces the diﬀerences among
them.
3. The extent of this improvement will depend on the exact problem, the sta-
tistical model used, and the number of replicates available.
4. Based on this work we recommend using a ﬁlter consisting of a minimum
absolute log2 fold change between 0.6 and 1, and a minimum mean signal
between 2 and 4 SpC in the most abundant condition. The higher the number
of replicates the lower the ﬁlter thresholds may be, still with good results.
With 4 replicates, the thresholds of 0.8 and 2 have given good results.
5. Long lists of DEPs could be favourably shortened by increasing the thresholds
in the post-test ﬁlter, instead of increasing the signiﬁcance level.
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4.3 Paper 3: A model for cell to cell comparisons
Enhancing the Biological Relevance of Secretome-based Proteomics by Linking Tu-
mor Cell Proliferation and Protein Secretion.
Gregori J., Me´ndez O., Katsila T., Pujals M., Salvans C., Villarreal L., Arribas J.,
Tabernero J., Sa´nchez A., Villanueva J.
Submitted to J. of Proteome Research, pending of publication.
4.3.1 Aim
Normalization is the approach used to guarantee that comparisons are made in
the proper scale. The aim of this work was to establish a normalization scheme
for cell-line secretomes where we wish to compare the amounts of protein secreted
by a single cell in two biological states.
4.3.2 Background
As seen in section 2.8.1, when equivalent quantities of total substance from two
biological states are compared, equation 2.12 provides an unbiased comparison.
4.3.3 Development of a cell-centric normalization
With cell line secretomes we may count the number of cells involved, and we
may measure the total quantity of protein secreted by these cells. This allows
to formulate a more general model which is valid even when there are serious
deviations from the basic assumption (see section 2.8.1).
We intend to compare the proteins secreted by one single cell in each of two
given biological states of a cell line, even when one state is globally stimulated
or depressed with respect to the other. Suppose we gather Qj μg of total protein
secreted by nj cells in the j-th biological condition, of which q μg are digested and
injected into the LC-MS/MS system to be measured.
The total quantity of digested protein measured is the same for the two con-
ditions. The ratio q/Qj gives the proportion of total secreted protein that gets
measured for condition j, hence (q/Qj)nj is the number of cells which secreted the
q μg in the j-th biological condition. Then we obtain the number of cells which






On the other hand given the expected SpC value μ of a protein at a given










As the total protein measured for the two biological conditions is the same, the
factor q contributes equally to both conditions and may be removed, bringing to










This allows to formulate a GLM model, as in equation 2.12, taking into account
the total spectral counts by sample, size, the protein production rate of each
condition, Q/n, the treatment factor, X, and a blocking factor to account for non






+ log(size) + α + βx+ γz (4.4)





exp(α + β + γz)
exp(α + γz)
= exp(β)
̂logFC = log2(exp(βˆ)) = 1.44βˆ (4.5)
where the subindex A stands for treatment, with x = 1, and subindex B for control,
with x = 0.
The p-value for diﬀerential secretion is obtained from the log likelihood ratio
test comparing the model given by 4.4 with the model with β = 0.
4.3.4 Findings
The hypothesis of diﬀerent secretion rates in diﬀerent conditions was veriﬁed by
observing large diﬀerences in the global protein secretion among cells experiencing
diﬀerent cellular perturbations, and even among cell lines at the basal state (see
Figure 4.8).
Then the general model formulated above was evaluated in two biological situa-
tions. First, the global protein secretion in a colorectal cancer cell line (SW48) that
has a large dependence on the epitelial growth factor receptor (EGFR) pathway
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Figure 4.8: Secretion rates of diﬀerent cancer cell lines in the basal state.
for its proliferation was evaluated. On one hand, the stimulation of the pathway
with exogenous EGF induces a high proliferative state in SW48 cells duplicating
the number of cells in 48h. On the other hand, the treatment with cetuximab, an
anti-EGFR, greatly blocks the proliferation of the cells. The results showed that
the high proliferative state induced by EGF yields a lower global protein secretion
as compared with the non-treated cells. Conversely, the blockage of proliferation
with cetuximab increases the global protein secretion by 3-fold compared to the
cells treated with EGF (Figure 4.9).
The second example is the epithelial to mesenchymal transition (EMT) in A549
lung cancer cells. The treatment of A549 cells with transforming growth factor beta
(TGFb) change their standard epithelial morphology to a spindle shape typical of
mesenchymal cells. In this case, global secretion is also aﬀected. The A549 cells
treated with TGFb secrete globally twice as much protein as the control cells. The
reason this model system was chosen is because EMT induces a massive change
in the cell’s secretome and its biology is reasonably well characterized. First,
the fold changes of EGF over Cetuximab were estimated for SW48 cells, and
TGFb over control for A549 cells. The estimation was done both under the model
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Figure 4.9: Secretion rates of a cell line under diﬀerent treatments.
normalizing just by total SpC, and under the proposed model. The resulting DEPs
were compared. The DEPs signiﬁcant only under the proposed model have been
previously linked to EMT, by either up- or down-regulating vimentin, E-caderin,
N-caderin or ﬁbronectin, or related to the EMT for other causes in diﬀerent studies.
Another observation was that cellular perturbations aﬀecting cellular prolifer-
ation had a large eﬀect on the amount of secretome produced by cells. This leads
to the hypothesis that global protein secretion and cellular proliferation could be
linked. An explanation could be that during mitosis, when the nuclear envelope
is dissolved and chromosomes are condensed, transcription is inhibited by the
hyper-phosphorylation of the transcription apparatus. Also during mitosis protein
transport between the ER and the Golgi apparatus is arrested, since the Golgi
stacks are disassembled.
To relate proliferation with secretion rate two of the most widely used breast
cancer cell lines, MCF-7 and MDA-MB-231 were taken. The MTT proliferation
assay conﬁrmed that MCF-7 cells grow almost twice as fast as MDA-MB-231.
Calculated doubling times of 25 h for MCF-7 and 42 h for MDA-MB-231 cells
contrast with a global protein secretion of 2.1 pg/cell and 4.3 pg/cell respectively.
This result shows the inverse proportionality between proliferation rate and global
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protein secretion.
Next, three colorectal cancer cell lines (SW48, LIM1215 and DiFi) were taken
and their cell proliferation was manipulated by stimulation with EGF and by
blocking with cetuximab (Figure 4.10). The global secretion rate in the cetuximab
condition approximately doubles that in the EGF condition. These experiments
further conﬁrm the inverse proportionality between proliferation rate and global
protein secretion, and suggest that proliferation rate play a role in the global
secretion rate of a cell.
Figure 4.10: Secretion rates vs proliferation.
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4.3.5 Conclusions
1. Cancer cell lines show diﬀerent global secretion rates at their basal state, or
under diﬀerent perturbations.
2. Under GLM, equation 4.4 provides an unbiased cell-to-cell comparison in
cell-line secretomes.
3. Our observations show that secretion rate and proliferation rate are inversely




All software was developed in the R statistical environment and language [R Core
Team, 2012]. Two R packages were produced with the code developed through-
out the works which brought to the publication of the above papers. They were
further reﬁned to fulﬁll Bioconductor [Gentleman et al., 2004] requirements, and
speciﬁcally adapted to work with instances of the MSnSet S4 class deﬁned in the
MSnbase package [Gatto & Lilley, 2012]. The packages are:
− msmsEDA for the exploratory data analysis (EDA) of SpC matrices.
− msmsTests for inference on SpC matrices, based on GLMs.
The functions provided for the EDA allow for the identiﬁcation of outliers and
potential batch eﬀects or confounding factors. Any BD study should systematically
start by an in-depth EDA to validate the model and samples used subsequently in
the study. The main msmsEDA functions are described in table 4.4.
The BD is conducted by the application of the same model and test to all the
proteins in the expression matrix. This means a replicated test for each row in
the matrix. The GLM models considered include the Poisson distribution, the
extension of the quasi-likelihood, and the negative binomial distribution. For the
Poisson and the quasi-likelihood, the test is on the likelihood ratio between the
alternative and the null model. For the negative-binomial the empirical Bayes
approach provided by the edgeR package is used [Robinson et al., 2010]. This
package has proven good results with few replicates in RNA-seq and demostrated
a good behaviour for SpC in our studies [Gregori et al., 2013]. The main msmsTests
functions are described in table 4.5.
Both packages include utility functions to help in the interpretation of the
results.
Availability
The packages have been integrated in the Bioconductor project [Gentleman et al.,
2004] and make use of the S4 class MSnSet in the MSnbase package [Gatto & Lilley,
2012].
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Figure 4.11: The two packages are available on-line at Bioconductor.
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pp.msms.data data preprocessing to replace NAs by 0 and
remove all zero rows.
gene.table extract gene symbols from protein descrip-
tion.
count.stats summaries of Spc and number of proteins by
sample.
counts.pca principal components analysis of the SpC
matrix.
counts.hc hierarchical clustering of samples.
norm.counts normalization of spectral counts matrix.
counts.heatmap experiment heatmap.
disp.estimates dispersion analysis by factor and plots.
spc.barplots barplots of the relative normalization divi-
sors.
spc.boxplots boxplots showing the distribution of SpC by
sample.
spc.densityplots density plots showing the distribution of SpC
by sample.
filter.flags ﬂag features by signal and variability thresh-
olds.
bacth.neutralize correct the batch eﬀects in the expression
matrix.
Table 4.4: Functions in the msmsEDA package.
msms.glm.pois Poisson based GLM regression
msms.glm.qlll Quasi-likelihood GLM regression
msms.edgeR The binomial negative of edgeR
pval.by.fc Table of cumulative frequencies of features
by p-values in bins of log fold change
test.results Multitest p-value adjustement and post-test
ﬁlter to ﬂag DEPs as likely reproducible.
res.volcanoplot Volcanplot of the results.
Table 4.5: Functions in the msmsTests package.
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− msmsTests vignette: LC-MS/MS post test ﬁlters to improve reproducibility
http://www.bioconductor.org/packages/2.13/bioc/vignettes/
msmsTests/inst/doc/msmsTests-Vignette.pdf
− msmsTests vignette: Bocks design to compensate batch eﬀects
http://www.bioconductor.org/packages/2.13/bioc/vignettes/
msmsTests/inst/doc/msmsTests-Vignette2.pdf
4.4.2 Graphical User Interfaces
Two graphical user interfaces have been developed to ease the routine lab compu-
tations, and to approach the solutions provided by the msmsEDA and msmsTests
packages to the researchers in the proteomics ﬁeld with no programming skills. The
GUIs have been developed based on the functions in the two R/Bioconductor pack-
ages, and with the help of the infrastructure provided by the R packages gWidgets
and RGtk2 [Verzani, 2012; Lawrence & Verzani, 2012; Lawrence & Temple Lang,
2010].
msmsEDA GUI
Allows an exploratory data analysis of a LC-MS/MS experiment given two ﬁles.
The metadata in the samples description ﬁle (targets), with samples identiﬁers,
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labels and eventual normalizing factors, and a ﬁle with the SpC expression matrix,
with proteins description and accessions (ﬁgure 4.12). A data quality assessment
is performed by boxplots and density plots of the observed SpC in each sample,
and by barplots of the relative normalization factor by sample. In this GUI,
the expression matrix is explored by PCA, HC and heatmaps. Both, with the
raw SpC matrix, with the sample size normalized SpC matrix, and after batch
eﬀects correction if a batch factor is provided in the metadata. The distribution
of informative features according to the main factor are also explored at each data
treatment step. Finally the distribution of residual dispersions is explored and
plotted. A number of ﬁles are generated with the results along with an index html
ﬁle with their names, description and link (ﬁgure 4.13).
msmsTests GUI
Given the metadata and the SpC ﬁles as above, this GUI provides great ﬂexibility
in BD with controls in the GUI which allow the choice of the normalization method,
the statistical test, the multiple test adjustment method, the signiﬁcance level, and
the post-test ﬁlter thresholds (ﬁgure 4.14). The output control in the GUI shows
the development of the computations and the main results. A number of text ﬁles
and pdf plots with the results are generated.
Availability and Documentation
The GUIs, and corresponding documentation, are available online at GitHub.com
msmsEDA GUI https://github.com/JosepGregori/msmsEDA GUI repos
msmsTests GUI https://github.com/JosepGregori/msmsTests GUI repos
A tutorial and the user guides of the two GUIs are attached to the thesis.
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Figure 4.12: The msmsEDA GUI window.
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Figure 4.13: Snapshot of the HTML index ﬁle with links to the ﬁles generated by
the EDA.
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Summary
A challenge in achieving optimal management of cancer is the discovery of se-
creted biomarkers that represent useful surrogates for the disease and could be
measured noninvasively. Because of the problems encountered in the proteomic
interrogation of plasma, secretomes have been proposed as an alternative source
of tumor markers that might be enriched with secreted proteins relevant to the
disease. However, secretome analysis faces analytical challenges that interfere with
the search for true secreted tumor biomarkers. Here, we have addressed two of the
main challenges of secretome analysis in comparative discovery proteomics.
The study included the following issues:
− Cell viability - degree of apoptosis
− Contamination by serum proteins
− Types of secretion
Statistic methods
All statistical computations were performed using the open-source statistical pack-
age R. The data from an MS/MS experiment was assembled in a matrix of spec-
tral counts where the diﬀerent conditions are represented by the columns, and the
identiﬁed proteins are represented in the rows of that matrix. The need for nor-
malization was assessed by comparing the total spectral counts (SpC) in technical
replicates of each sample. As the quantity of substance for each sample, in each
experiment, was the same, any substantial deviation was corrected by normalizing
to the median total sample counts. An exploratory data analysis by means of prin-
cipal components analysis (PCA) and hierarchical clustering (HC) of the samples
on the SpC matrix was performed to ﬁnd potential outliers and patterns in the
data. Dealing with counts precludes the use of statistical tests and procedures
based on the normal distribution, and restricts the appropriate methods to those
in the general frame of the Generalized Linear Models (GLM) with discrete dis-
tributions. As no substantial biological variability is expected from cell line data,
according to our experience, a Poisson regression was used for signiﬁcance testing
throughout this work. The GLM model based on the Poisson distribution was
used as a signiﬁcance test throughout our work. Finally we used the Benjamini
and Hochberg multiple test adjustment [Benjamini & Hochberg, 1995].
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Results
First, we carried out a kinetics experiment whereby secretomes and lysates of tu-
mor cells were analyzed to monitor cellular viability during secretome production.
Interestingly, the proteomic signal of a group of secreted proteins correlated well
with the apoptosis induced by serum starvation and could be used as an internal
cell viability marker. We then addressed a second challenge relating to contam-
ination of serum proteins in secretomes caused by the required use of serum for
tumor cell culture. The comparative proteomic analysis between cell lines labeled
with SILAC showed: i) a number of false positives coming from serum, and ii)
that several proteins are both in serum and secreted from tumor cells.
A thorough study of secretome methodology revealed that under optimized ex-
perimental conditions there is a substantial fraction of proteins secreted through
unconventional secretion in secretomes. Finally, we showed that some of the nu-
clear proteins detected in secretomes change their cellular localization in breast
tumors, explaining their presence in secretomes and suggesting that tumor cells
use unconventional secretion during tumorigenesis. The unconventional secre-
tion of proteins into the extracellular space exposes a new layer of genome post-
translational regulation and reveals an untapped source of potential tumor biomark-




During the development of this thesis I was also working on NGS data, devel-
oping tools for the analysis of sequences of amplicons of viral quasispecies. In
what follows there is a summary of the publications in international peer-reviewed
journals, with title and abstracts.
1. Diversity in quasispecies by CCSS and NGS
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2. Minority variants in HCV quasispecies
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3. Minority variants in HBV quasispecies. Cloning vs NGS
111
4. HCV infection by sex transmission. A case study
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5. Ribavirin as a HCV mutagen
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This work focused on three relevant aspects of biomarker discovery (BD): batch
eﬀects, reproducibility, and the design of a model for cell-to-cell comparisons for
cancer cell-line secretomes.
We studied the incidence of batch eﬀects [Scherer, 2009] on label-free compar-
ative proteomics based on SpC, and ﬁxed the most narrow time window where
LC-MS/MS runs are equally inﬂuenced by uncontrolled factors in one single day
of data acquisition [Gregori et al., 2012]. The batch eﬀects were evidenced by
multidimensional techniques like PCA or HC. We then studied possible ways to
correct these batch eﬀects [Chen et al., 2011] in balanced comparative experiments,
and found that the best correction is the scale correction implemented in a log-link
GLM with a batch blocking factor [Quinn & Keough, 2002].
On the basis of the conceptual aspects of the MAQC-I recommendations [Shi
et al., 2008] we studied the advantages in using post-test signal and eﬀect size ﬁlters
to improve the reproducibility of biomarkers discovered by label-free LC-MS/MS
with SpC. We found that with these ﬁlters we may improve the number of true
positives (TP), while restricting the number of false positives (FP), by relaxing
the signiﬁcance level. We found also that the use of this sort of ﬁlter gives the
additional advantage of improving the overlap in the lists of proteins declared as
diﬀerentially expressed using diﬀerent tests [Gregori et al., 2013].
Starting from the most general hypothesis of a variable secretion rate of cancer
cell-lines under diﬀerent biological conditions we developed a GLM model for unbi-
ased cell-to-cell secretome comparisons (see section 4.3). This model incorporates:
i) a sample size normalization by the total SpC in the sample, ii) the cell-to-cell
normalization using the observed secretion rate, iii) the relevant treatment factor
for the comparison, and iv) blocking factors.
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The R code produced during these studies was structured in functions of gen-
eral use and transformed in two Bioconductor [Gentleman et al., 2004] packages.
One for the exploratory data analysis that evidences outliers, batch eﬀects and
confounding factors (msmsEDA). And a second implementing the tests and ﬁlters
(msmsTests). Two graphical user interfaces (GUI) using these two packages were
also produced (msmsEDA GUI and msmsTests GUI).
In the next sections we discuss what is missing or what could be developed
next.
5.1 Limitation in the use of SpC
The discrete nature of the SpC complicates the interpretation of very low levels
of expression, where the quantitation by ion intensity could be more reliable (see
section 2.5). Or at least not as of the black and white condition.
Either with the tests or when using the post-test ﬁlter to improve reproducibil-
ity, the quality in the results at this low level will depend of the number of repli-
cates, as long as the average expression within biologic condition loses its discrete
nature. That is, in the measure that low mean values acquire more entropy. This
means that the lower the level of expression on which we are interested, the higher
the number of required replicates.
5.2 Batch eﬀects in diagnostics
Despite the fact that batch eﬀects may be visualized, quantiﬁed, and corrected
in balanced experiments, a question remains in how to deal with isolated samples
in LC-MS/MS. In biomarker discovery (BD) there seems to be no alternative to
minimally balanced experiments [Scherer, 2009]. The number of samples of each
condition in a batch has to be adjusted according to the capabilities of one single
day of LC-MS/MS in the lab [Gregori et al., 2012]. And the samples in a batch
have to be processed in parallel from the very beginning to the ﬁnal LC-MS/MS
measurement [Quinn & Keough, 2002]. The question to answer is how to measure
a new single sample of unknown condition to be classiﬁed (diagnosed).
In most cases the biomarker could be a single protein, or a very limited number
of proteins, which could be measured by a direct immunochemical test where batch
eﬀects are limited or of no concern. In some cases, where the combination of signal
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and eﬀect size is not strong enough for any single protein, the biomarker could be
a signature composed of a higher number of proteins which could recommend the
use of LC-MS/MS in diagnostics.
To answer the question in this latter case we must distinguish between sample
normalization, which is a transformation by columns, and the batch eﬀects, which
is row dependent because each peptide may have a diﬀerent response to the global
uncontrolled factors. Normalization of a new sample by the total number of SpC,
and eventually by the protein production rate of a cell-line, poses no problems
provided that the total quantity of protein measured is the same. On the other
hand avoiding confusion due to uncontrolled factors will require a control sample
measured immediately after. This control sample must be stable in time and
contain all the relevant proteins in due concentrations. Both samples must be
processed in parallel so that they may constitute a single batch, in that they are
equally inﬂuenced by all uncontrolled factors [Quinn & Keough, 2002]. This is not
at all simple and requires further study and assessment.
5.3 Underdispersion
Although the main concern in most methods developed for comparative proteomics
is overdispersion caused by biologic variability (see section 2.7.3), in the experi-
ments with controlled samples of yeast lysate we observed a signiﬁcant degree of
underdispersion. This was consistently observed at all levels of expression (Figure
5.1). That is, the observed variance was mainly below the observed mean expres-
sion. In diﬀerent experiments with cell-line secretomes we observed some degree
of underdispersion as well.
Any model able to describe this reduced variance could beneﬁt from a higher
sensitivity than the Poisson GLM. Both the negative-binomial distribution (see
equation 2.10), and the quasilikelihood extension to the GLM (see equation 2.11)
may account for underdispersion as well as for overdispersion. The quasilikelihood
models underdispersion with positive values of ψ below 1, the negative-binomial
models underdispersion for negative values of φ above −1/μ [Agresti, 2002].
The estimation of the dispersion introduces a second parameter in the model,
requiring then a higher number of replicates, which is the biggest limitation in
a proteomics lab, where scarcely more than three replicates are aﬀordable. The
solution provided by edgeR [Robinson et al., 2010], similar to that implemented in
limma [Smyth, 2005] for microarrays, allows to share information across proteins,
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Figure 5.1: Residual dispersion in the experiments with yeast lisate spiked with
human proteins. The dots under the diagonal show underdispersion.
and alleviates the need for a higher number of samples. An interesting work could
be to study and develop a similar empirical Bayes approach, such that used in the
mentioned packages, for the quasilikelihood.
5.4 Possible uses in other omics
This thesis has been developed on datasets which are sparse matrices of counts
similar to those observed in at least other two omics : RNA-seq tables in transcrip-
tomics [Wang et al., 2009] and OTU tables in metagenomics [Wooley et al., 2010],
both using NGS technologies but answering quite diﬀerent questions. In this re-
spect, besides speciﬁc normalization issues, studying diﬀerential protein secretion
in cancer cell-lines represents similar statistical challenges as studying diﬀerential
gene expression by RNA-seq, or diﬀerential abundance in microbiomes by 16S
rRNA sequencing. Speciﬁcally the edgeR package [Robinson et al., 2010] used in
our software was developed for RNA-seq analysis.
In both omics reproducibility is a key issue and the batch eﬀects correction
and post-test ﬁlters could contribute to improve the results in all of them. The
implementation of some of the solutions provided by this work to these other omics
should not be mimetic because of speciﬁcities of each ﬁeld, but could constitute a
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good basis.
5.5 What next ?
With the model in equation 4.4, comparative proteomics with secretomes based
on SpC may be considered unbiased, provided that sample batches are minimally
balanced in the conditions to compare. This imposes a restriction of the sort
observed for labelled proteomics. A possible solution to this shortcoming could
be to use a universal control sample, so that any condition could be measured
against this control. This could allow the unbiased comparison of conditions in
diﬀerent batches having the same control samples. Although conceptually simple
this possibility deserves a careful study, and it is not clear whether a diﬀerent
universal control sample could be appropriate for diﬀerent cell-lines. The batch
eﬀects could be corrected just for the proteins in common among the conditions to
be compared and the control samples, and provided that the expression level is of
the same order. This study requires extensive experiments and attention and may
constitute the basis for a new project, along with the considerations in diagnostics
brieﬂy pointed out above (see 5.2).
One remaining important issue is the validation of biomarker signatures in
proteomics. When the BD process brings to one single or very few molecules,
the validation will be done by methods diﬀerent to LC-MS/MS, as ELISA for
instance. Instead, when the BD process brings to a complex mixture of proteins, to
a proteomic signature, discovery and validation become part of the same problem,
and attention has to be given to avoid the overﬁtting of the signature to the
dataset used in BD. One interesting line of study could be the implementation
in proteomics of the general methodology proposed by [Parry et al., 2010] for
microarrays on the light of the MAQC-II study [Shi et al., 2010].
Finally, another possible project could be to study the incidence of the batch
eﬀects, and the required levels of post-test ﬁlters to improve reproducibility when





This thesis has explored essential aspects of biomarker discovery by spectral counts
in label-free shotgun proteomics by LC-MS/MS, studing cancer cell-lines secre-
tomes. Speciﬁcally, it has been shown that:
1. Normalizing by total SpC by sample in technical replicates results in a more
stable normalization than using internal standards, even when multiple stan-
dards are used.
2. Batch eﬀects are likely present on every proteomics project done for more
than one day of instrument data acquisition.
3. An exploratory data analysis is a necessary step to assess the quality of a
dataset, to identify putative outliers, and eventual batch eﬀects and con-
founding factors.
4. Fully unbalanced LC-MS/MS runs will likely produce biased results. The
eventual bias cannot be corrected by any means.
5. Batch eﬀects may and should be corrected in balanced experimental designs.
6. A post-test ﬁlter with reasonable eﬀect size and signal level thresholds helps
to increase the reproducibility of comparative proteomic analysis.
7. Long lists of DEPs could be favourably shortened by increasing the thresholds
in the post-test ﬁlter, instead of using a more stringent signiﬁcance level.
8. Cancer cell lines show diﬀerent global protein secretion rates at their basal
state, or under diﬀerent perturbations.
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9. Under GLM, equation 4.4 provides an unbiased cell-to-cell comparison in
cell-line secretomes.
10. Secretion rate and proliferation rate seem to be inversely correlated for a
given cell-line.
11. Finally, the developed solutions and the designed model have been imple-
mented in two R/Bioconductor packages, msmsEDA and msmsTests, and its
dissemination and use by non-experts has been facilitated by two graphical
interfaces, msmsEDA GUI and msmsTests GUI.
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